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Cover illustration 
My first love in science was the stars and planets, and for some years I dreamt about 
becoming an astronaut and exploring the universe above. In cancer research I found a 
starry sky in the FISH microscope, where bright signals in different colors resembled 
the stars I had dreamt about as a child. Even though we now know more about the 
components inside the body, sometimes it feels as if we have a whole universe within 
where only few stars have been fully characterized.  
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Introduction 
Cancer and cytogenetics–from mysterious lumps to chromosomal barcodes 
One of the first known descriptions of cancer is found in a papyrus which scientists 
have dated to approximately 2500 BC (Mukherjee, 2011). It is believed to be the 
teachings of the Egyptian physician Imhotep and describes patients with various 
medical conditions. One description tells about a woman with a hard, bulging mass of 
the breast, without fever or discharging fluids. This is most likely a description of a 
woman with breast cancer. In addition to written reports, solid evidence of cancer has 
been detected in mummified bodies with bone tumors (Mukherjee, 2011). These 
ancient findings imply the coexistence of man and neoplasia for as long as we have 
been here.  
Throughout history, likewise, many theories of the origin of cancer have been 
proposed. Hippokrates (460-370 BC), referred to by many as the father of Western 
medicine, adhered to the dominant theory of his time believing that the body had four 
fluids or humors (black bile, yellow bile, phlegm, and blood) and that cancer was 
caused by an imbalance affecting predominantly the black bile (American Cancer 
Society, 2009). This humoral theory more or less held sway until the mid nineteenth 
century when the German pathologist Rudolph Virchow established cellular pathology 
as the new paradigm of disease, and especially cancerous diseases. One of Virchow’s 
assistants, David Hansemann, studied mitoses in several human tumor types and 
documented mitotic asymmetries in most of them; this he realized might point to a 
mechanism of carcinogenesis. This line of thinking matured into the somatic mutation 
theory of cancer suggested by Theodor Boveri in 1914. His theory was based on 
studies of fertilized sea-urchin eggs, originally enough, but led to our current standard 
understanding of the principles of tumorigenesis (Balmain, 2001). Boveri observed 
that eggs fertilized with two sperm cells sometimes developed an unequal distribution 
of chromosomes in the daughter cells. Some of these cells died, but some lived on with 
an abnormal appearance. Boveri therefore suggested that individual chromosomes 
must possess different abilities, and that some abnormal combinations of 
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chromosomes could create abnormal growth. In retrospect, his assumptions fit 
surprisingly well with the theory of proto-oncogenes and tumor suppressor genes 
discovered over 70 years later (Balmain, 2001). It is today generally accepted that 
cancer is a genetic disease caused by DNA sequence changes (Stratton et al, 2009).  
The next major contribution to cancer genetics came in 1960 when Nowell and 
Hungerford identified a minute chromosome, called the Philadelphia chromosome, in 
the bone marrow cells of patients suffering from chronic myeloid leukemia (CML) 
(Nowell and Hungerford, 1960b). This was the first specific chromosome abnormality 
to be detected in cancer. Cytogenetic analysis experienced a boom in the 1970s after 
the development of banding protocols for human chromosomes (Caspersson et al, 
1968). Until then chromosomes had been arranged according to their size in 23 
matching pairs and grouped after the location of their centromere (Trask, 2002). The 
new staining techniques revealed dark and light bands across the arms of the 
chromosomes, and these soon became the bands of reference for classifying normal 
and aberrant chromosomes. Modern cancer cytogenetics is an important tool for an 
initial screening of the cancer genome, both in diagnostics and research. Cytogenetic 
studies have greatly improved our understanding of carcinogenesis of especially 
hematological and mesenchymal neoplasias (Heim and Mitelman, 2009).  
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The BCR-ABL story 
 
Figure 1: The formation of the BCR-ABL fusion gene is caused by a translocation of 
the long arm of chromosome 9 to chromosome 22. Below the schematic presentations 
is a photo of the normal chromosome 22 and the smaller “Philadelphia” chromosome. 
 
Nowell and Hunderfords’s finding, the so called “Philadelphia chromosome” in 
patients with CML (Nowell and Hungerford, 1960b) (Figure 1), turned out to be one of 
the most seminal in the history of cancer genetics. This chromosome, named after the 
city in which it was discovered, is specific for chronic myeloid leukemia. In the early 
1970s, it was discovered that it resulted from a translocation between chromosomes 9 
and 22 (Rowley, 1973, Goldman, 2010). On chromosome 9, the ABL1 gene was 
involved (de Klein et al, 1982). In 1984, the breakpoint on chromosome 22 was shown 
to occur within a 5.8 Mb area called the breakpoint cluster region (today the BCR 
gene) (Groffen et al, 1984). The fusion of these two genes results in a qualitatively 
new gene that encodes an aberrant tyrosine kinase which is crucial for CML 
development (Lugo et al, 1990, Deininger et al, 2000). Based on this knowledge, 
   Introduction 
 
14 
 
Druker and colleagues searched for compounds that could specifically bind and inhibit 
the BCR-ABL1 protein (Druker et al, 1996). Their finding, a tyrosine kinase inhibitor 
(TKI) called imatinib, has since revolutionized treatment of CML patients (Druker, 
2002). Although imatinib does not cure the patients of their disease, it gives long-term 
remissions without significant side effects in the majority of patients, and it is today 
the first choice of treatment for newly diagnosed patients with chronic phase CML 
(Baccarani et al, 2006).  
Targeted cancer therapy 
Targeted therapy aims to interfere with a molecular target essential for cancer cell 
growth and survival. In contrast to classical chemotherapy, targeted therapy aims to 
kill cancer cells more selectively and thus avoid the adverse side effects and general 
toxicity of cytostatics (Sawyers, 2004). A potential target for therapy should be (1) 
necessary and sufficient for cancer cell survival, (2) expressed and active in the tumor, 
(3) inhibiting effector molecules for which no possible circumventions in the implied 
pathway is possible (Borden et al, 2003). Inhibition with imatinib of the mutant kinase 
chimeric protein BCR-ABL1 in CML is the most successful example of this approach, 
even though resistance ultimately will develop (see above). However, in most other 
cancers where TKIs have been tested, patients develop resistance within a shorter time 
frame (Sierra et al, 2010). Efforts are now being made to try to understand the 
mechanisms underlying resistance both in vitro and in vivo.  
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Cytogenetic nomenclature  
Tjio and Levan detected in the mid 1950s (Tjio and Levan, 1956) the correct human 
chromosome number of 46 (44 autosomes and 2 sex chromosomes) after it had been 
believed for many years that 48 was the correct number. In the years after, research in 
this field expanded and a common system for cytogenetic nomenclature was needed. 
The first generally accepted cytogenetic nomenclature was established at a meeting in 
Denver in 1960, and this became the forerunner of today’s International System for 
Cytogenetic Nomenclature (ISCN) (Shaffer et al, 2009). Cytogenetic nomenclature is 
based upon the chromosomal banding pattern and the occurrence of other specific, 
distinct morphological hallmarks. Chromosomes are arranged by their size and the 
location of the centromeres. Accordingly, chromosome 1 is the largest chromosome, 
chromosome 2 the second largest and so on, with one exception, that chromosome 21 
is smaller than chromosome 22 (Shaffer et al, 2009). The chromosomal bands appear 
by the differential staining throughout the chromosomes and are defined as “a part of a 
chromosome that is clearly distinguishable from its adjacent segments by appearing 
darker or lighter with one or more banding techniques”(Shaffer et al, 2009). The 
shorter chromosome arm is designated the “p” arm, while the longer arm is called the 
“q” arm. The chromosomal location 2p13 therefore designates chromosome 2, the 
short arm, region 1 within that arm, and band 3 within that region (Figure 2). 
 
Figure 2: Graphic presentation of a chromosome. See text for details. From: Essential 
Haematology, 6th Edn. © Hoffbrand A.V. and Moss P.A.H., Blackwell Publishing, 
2011 (with permission) 
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Nomenclature of abnormal chromosomes 
Chromosomal aberrations are divided in two groups after their nature: structural and 
numerical. Structural aberrations are rearrangements of one or more chromosomes, 
whereas numerical aberrations refer to copy number changes (Heim and Mitelman, 
2009). The most common structural aberrations are translocations, deletions, and 
inversions. They can be balanced, with no net gain or loss of genetic material, or 
unbalanced, implying unequal exchange of genetic material. Several other 
abnormalities can be seen and a specific terminology is used for karyotypic 
descriptions. A list of cytogenetic abbreviations can be found in Table 1. Only clonal 
chromosomal abnormalities are reported in karyotypic descriptions. A clone is defined 
as a group of cells stemming from a single progenitor cell, and at least two cells with 
the same structural aberration must be detected in order to infer the existence of a 
clone when doing cytogenetic analyses (Shaffer et al, 2009). If the aberration is 
numerical, that is loss or gain of a whole chromosome, two cells are needed for a 
supernumerary chromosome to be considered clonal, and three cells if the 
chromosome is lost. Clonally related cells share one or more aberrations, but 
additional abnormalities can be detected as a part of clonal evolution.  
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Rearrangement Abbreviation Description 
Addition add 
Addition of material of unknown 
chromosomal origin 
Composite cp 
Composite karyotype describes all 
clonally occurring abnormalities 
in a cytogenetically heterogeneous 
tumor 
Deletion del 
Deletion (terminal or interstitial); 
loss of chromosomal material 
seemingly including or not 
including the tip of the 
chromosome arm 
Derivative der 
Structurally rearranged 
chromosome 
Marker mar 
Abnormal chromosome that 
cannot be identified  
Translocation t 
Interchanges of material between 
two non-homologous 
chromosomes 
Table 1: Cytogenetic abbreviations relevant for this thesis 
Consequences of balanced chromosomal translocations  
Balanced chromosomal translocations involve swapping of material between two 
chromosomes with no net gain or loss of chromosomal material. Two main 
pathogenetic consequences may in the cancer context follow from such translocations: 
either two genes are fused with each other and a qualitatively new hybrid or fusion 
gene is formed, or one gene loses or gains regulatory elements leading to its aberrant 
expression (Mitelman et al, 2007) (Figure 3). Translocations can also be present 
without any known consequences. Some of these are probably non-recurrent changes 
seen in unstable cancer genomes, but others might involve as yet undiscovered 
mechanisms leading to growth advantages for the cancer cell.  
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Figure 3: The two main consequences of chromosomal translocations are illustrated; 
the formation of a fusion gene and the dysregulation of a normal gene. The bars 
indicate exons while the circle illustrates a regulatory element.   
 
Fusion genes 
Fusion genes are hybrid genes formed by the fusing together of two previously 
separate genes. If joined properly, the new gene may give rise to a new chimeric 
protein with novel and oncogenic properties different from those of the native proteins. 
Based on cytogenetic studies, it has been estimated that fusion genes account for about 
20% of cancer morbidity (Mitelman et al, 2007), but this may well be only the tip of 
the iceberg. Most known fusion genes are found in leukemias, lymphomas and 
mesenchymal tumors, while fewer have so far been found in the more common 
epithelial cancers. This does not necessarily mean that fusion genes in fact are more 
common in these rare tumor types, it may rather reflect the number of cytogenetically 
analyzed cases or the ease with which fusion genes are found in different settings 
(Mitelman et al, 2004). Studies relying on new investigative technologies are now 
revealing fusion genes on a much larger scale than was previously acknowledged, 
Introduction 
 
19 
 
especially in epithelial cancers (Edwards, 2010). The number of known fusion genes in 
cancer has increased from about 100 in the year 2000 (Mitelman, 2000) to 1603 as of 
August 14, 2013 (Mitelman et al, 2013). Recurrent fusion genes have now been 
detected also in common epithelial cancers such as carcinoma of the prostate (Tomlins 
et al, 2005), lung (Soda et al, 2007), breast (Stephens et al, 2009), and colon (Bass et 
al, 2011). Some of the cases analyzed revealed multiple fusion genes within the same 
tumor, with hitherto unknown oncogenic potential (Maher et al, 2009). In 
mesenchymal tumors, a fusion gene is often found in a high proportion of cases within 
each diagnostic entity. By comparison, the fusion genes identified so far in carcinomas 
have been found in a much lower percentage of cases.  
Several aspects make the fusion genes of cancer interesting to study and some of them 
will be discussed below. For many of the well-described fusion genes there is 
convincing evidence for an important role in cancer cell survival and initiation 
(Mitelman et al, 2007). Identification of new fusion genes may therefore locate new 
players in the complex process of carcinogenesis. In addition, the detection in a tumor 
sample of a specific fusion gene can help resolve diagnostic dilemmas. An example is 
the finding of FUS-DDIT3 in a lipomatous tumor. This means that the tumor is a 
myxoid liposarcoma resulting from a t(12;16)(q13:p11); over 80% of myxoid 
liposarcomas harbor this translocation (Fletcher et al, 2013). This is not a unique 
example; in fact, most fusions are specific for certain cancer types. Certain gene 
fusions occur across several cancer types. ETV6-NTRK1 is such a fusion gene, which 
has been detected in secretory breast cancer (Tognon et al, 2002), congenital 
fibrosarcoma (Knezevich et al, 1998), and acute myeloid leukemia (Eguchi et al, 
1999). Phenotypic tumor classifications will therefore always be needed. Furthermore, 
and maybe most interestingly, the fusion genes may represent therapeutic targets 
unique to the tumor in question. The main problem with current chemotherapeutics is 
their lack of specificity. The drugs kill all dividing cells, causing severe side-effects to 
the patient and reducing the dosage the patients can tolerate. Again, the imatinib story 
demonstrates the success of this approach. Imatinib treatment has increased survival 
and is generally well tolerated by CML patients (Druker, 2008). 
   Introduction 
 
20 
 
Gene deregulation 
If a chromosomal rearrangement does not lead to the formation of a fusion gene in a 
cancer, chances are good that it juxtaposes regulatory sequences from one gene with 
the transcribing parts of the other gene, which usually is a proto-oncogene, and 
therefore gives rise to the latter gene’s activation. As the DNA structure is three-
dimensional, also promoters far from the translocation breakpoint can affect gene 
transcription. One well-known example of gene deregulation following a translocation 
is the juxtaposition of the proto-oncogene MYC, from 8q24, to the vicinity of an 
immunoglobulin gene. This deregulation is typical of Burkitt lymphoma (Hecht and 
Aster, 2000) and leads to constitutive overexpression of MYC. In other cases, genes at 
translocation breakpoints may be inactivated by the chromosomal rearrangement. This 
seems to be rare, and the functional consequences are often difficult to predict 
(Mitelman et al, 2007), however the result could be loss of tumor suppressor function. 
The affected genes can either be translated into truncated transcripts or be degraded as 
a consequence of the cellular quality control system for example by a mechanism 
called nonsense-mediated decay that recognizes preterm stop-codons (Chang et al, 
2007). The result would be an aberrant protein with unknown functional 
consequences, in the former case, and lack of the protein in the latter. 
The human miRNA genes, which are small, non-coding RNA molecules with 
influence on transcriptional and post-transcriptional regulation of gene expression, are 
non-randomly located at hot spots for chromosomal rearrangements (Calin et al, 
2004). Translocations in these areas may lead to deregulation of protein coding genes 
in a manner similar to that seen in lymphomas (Calin and Croce, 2007). Also, genes 
can contain binding sites for miRNAs with repressive functions. Disruption of these 
sites through chromosomal translocations may lead to overexpression of the affected 
genes. An example of this mechanism is found in translocations involving 12q13-15 
affecting the HMGA2 gene (Mayr et al, 2007) (paper II). 
Rearrangements without functional consequences 
Rearrangements may also occur in non-coding areas of DNA with no functional gene 
alteration resulting. The rarity of reports describing this phenomenon may be due to 
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publication bias, i.e., journals are less likely to publish negative results. The possibility 
is well illustrated by individuals carrying a balanced translocation with apparently 
normal phenotypes. Approximately 1 of 1000 newborns are estimated to carry such a 
translocation (Ferlin et al, 2007), and because all transcribed genes are intact, no 
functional consequence is apparent. The translocation might first be detected when an 
affected individual turns out to be infertile or have spontaneous abortions because of a 
higher likelihood of genomically unbalanced offspring. 
Submicroscopic rearrangements around breakpoints 
Not all seemingly balanced translocations turn out to be exactly balanced when 
analyzed at the base pair level. Deletions (Sinclair et al, 2000), inversions (Desmaze et 
al, 1997, Micci et al, 2006), paper III), and duplications (Howarth et al, 2011) in and 
around the translocation breakpoints may accompany what looks cytogenetically as 
balanced changes, both in malignant diseases and in constitutional translocations. This 
possibility should be kept in mind when searching for fusion genes; it could account 
for otherwise difficult-to-explain findings made during the study. In addition, the true 
prevalence of this phenomenon might be underestimated as such a rearrangement 
makes the characterization of the breakpoint more difficult.  
Acute leukemias and sarcomas 
Hematological and mesenchymal malignancies were the targets of studies leading up 
to this thesis. Both originate from the mesoderm and in both types of neoplasia, 
balanced translocations leading to fusion genes are often identified (Mitelman et al, 
2007).  
The term leukemia (from Greek leucos: white, and haima: blood) was first used by the 
German pathologist Rudolf Virchow in 1847 (Kampen, 2012). He believed the disease 
to be caused by too many white blood cells. Today, leukemia is known to be a clonal 
neoplastic disease of hematopoietic cells. By way of operational definition, acute 
leukemia is said to be present when the bone marrow contains >20 percent immature 
cells or blasts. Depending on the leukemic cell lineage commitment, the acute 
leukemias are divided into acute lymphoblastic leukemia (ALL) if the cells resemble 
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immature lymphatic cells (in which case they are assumed to originate from cells of 
lymphoid origin) and, correspondingly, acute myeloid leukemia (AML) if made up of 
immature myeloid cells (Swerdlow, 2008). The term “acute” in contrast to “chronic” 
originally referred to the rapid course of the acute form of the disease; in current times, 
it reflects the immature nature of the cells of the acute leukemias. Acute leukemia can 
be fatal within days to weeks if not adequately treated. Signs of leukemia are caused 
by the replacement of the normal bone marrow cells by a malignant leukemic clone, 
and include manifestations brought about by anemia, thrombocytopenia, and 
neutropenia. As a consequence, patients with leukemia usually present with fatigue, 
bone pain, headache, infections, bleedings or other unspecific signs and symptoms.  
Leukemias have in later decades been classified according to the FAB (French-
American-British) system first launched in 1976 (Bennett et al, 1976) which is based 
on morphological and cytochemical leukemic cell features. Since 2001, the World 
Health Organization (WHO) classification has largely superseded previous 
classifications (Swerdlow, 2001). In addition to cell morphology, the WHO system 
includes immunophenotype and genetic characteristics in the classification.  
ALL is divided in two main subgroups, those expressing B cell and those expressing T 
cell features, whereas AML is divided in six subgroups depending on the maturation 
level and the predominantly affected cell type. While ALL is primarily a disease of 
children with most cases being diagnosed in patients under 18 years of age (Swerdlow, 
2008), AML is much more common in adults with a median age at diagnosis of about 
70 years (Smith et al, 2011). 
Known risk factors for the development of leukemias, especially the myeloid ones, 
include exposure to organic solvents such as benzene (Galbraith et al, 2010) and 
previous treatment with chemotherapeutic drugs (Czader and Orazi, 2009), but in the 
majority of cases no etiologic factor can be identified (Zeeb and Blettner, 1998).  
When treating patients with acute leukemia, the first goal is to obtain a complete 
remission using chemotoxic agents. Whether this can be accomplished depends on 
how well the patient tolerates the induction treatment, their performance status at 
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diagnosis, co-morbidities, and biological properties of the neoplastic disorder. 
Cytogenetic abnormalities, along with other criteria, determine the risk classification 
and therefore indirectly influence the further treatment in each group (Vardiman et al, 
2009). In the medium and high risk groups, hematopoietic cell transplantation during 
first remission is an option for young patients with good performance status, but the 
treatment is dependent of the existence of a HLA-matched donor and associated with 
several adverse side effects.  
Sarcomas (from Greek sarx: flesh, and oma: tumor) are tumors replicating connective 
tissue architectural features and which presumably originate from cells of 
mesenchymal origin. They are anatomically subdivided into bone and soft tissue 
tumors (Fletcher et al, 2013). Sarcomas occur in all age-groups and usually present as 
a hard, painless swellings. They account for only 1 % of human malignant neoplasms 
(Fletcher et al, 2013). Sarcomas can be further subdivided into over 70 different 
histological subtypes according to the WHO (Fletcher et al, 2013). Another way of 
classifying sarcomas, in principle independently of their histological appearance and 
tissue of origin, is based on their cytogenetic changes (Taylor et al, 2011). Tumors in 
the first group harbor simple chromosomal rearrangements or near-diploid karyotypes 
while those of the other group typically display complex karyotypes with both 
numerical and structural rearrangements. In sarcomas with simple karyotypes (about a 
third of all sarcomas), fusion genes are often detected (Mitelman, 2000). Some of these 
fusion genes are tightly linked to a histological disease entity, as for example Ewing 
sarcoma. In this malignancy, the majority of cases display a t(11;22) leading to a 
fusion between the EWSR1 and the FLI1 genes (Delattre et al, 1992, Fletcher et al, 
2013). Some sarcomas harbor instead activating point mutations in key genes, with 
gastrointestinal stromal tumors (GISTs) as the most thoroughly studied example. The 
majority of GISTs have a mutated tyrosine kinase gene which renders them susceptible 
to TKI treatment (Hirota et al, 1998, Heinrich et al, 2003). 
Most sarcomas arise without any known etiology, but some genetic syndromes such as 
the Li-Fraumeni syndrome (Li et al, 1988) and neurofibromatosis type I (Ferner and 
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Gutmann, 2002) predispose to sarcoma development, as does previous radiation 
therapy (Bjerkehagen et al, 2008). 
 Limb-sparing surgery can be sufficient for cure in some patients with small tumors 
and no metastasis at diagnosis, but for most patients, multimodal approaches with 
combinations of chemotherapy and radiotherapy together with surgery are offered 
(Fletcher et al, 2013). Due to the rarity of sarcomas and especially tumors of 
individual subgroups, even multicenter trials spend years to include enough patients to 
conduct randomized trials for evaluation of new treatments. Therefore, it is difficult to 
obtain well-founded protocols. In research settings, it is possible to try new drugs 
based on a theoretical rationale for example in terminal ill patients. The first GIST 
patient treated with imatinib (Joensuu et al, 2001) demonstrated the potential success 
of this approach. A shift from a classification based on histological appearance to a 
genetic signature in these rare cancers may facilitate the introduction of new drugs. 
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Methods 
The techniques described here are the main methods used in the studies behind this 
thesis. All methods have advantages as well as limitations, and some of them will be 
discussed in the following, together with a brief overview of the theoretical 
background underlying each method.  
Fluorescence in situ hybridization  
Fluorescence in situ hybridization (FISH) is a procedure based on the principle that 
complimentary DNA or RNA sequences hybridize to each other. The first 
hybridization using radioactively labeled DNA probes was described in the late 1960s 
(Pardue and Gall, 1969). Further development of hybridization techniques came in the 
early 1980s, after the discovery of the usefulness of fluorescent tags for labeling. 
These dyes are safer and simpler to handle, furthermore they can be stored for longer 
periods (Trask, 2002). These advantages led to several new applications for the 
method: characterization of chromosomal rearrangements, detection of microdeletions, 
and prenatal diagnosis of common congenital aneuploidies (Fan, 2002).  
Three main types of FISH probes exist: locus-specific, whole chromosome painting, 
and repetitive sequence probes. Locus-specific probes hybridize to a defined area of 
interest in the genome. Whole chromosome painting probes contain a pool of DNA 
fragments all hybridizing on the same chromosome so that it appears fluorescent and 
can be easily identified in a metaphase. The repetitive sequence probes map to an 
amplified sequence in the genome. An example of the latter is the centromeric probe 
targeting pericentromeric sequences. They are well suited for detection of numerical 
aberrations either in interphase nuclei or if metaphase quality is poor (Moyzis et al, 
1987).  
The resolution of the experimental FISH approaches rapidly improved. By 1985 the 
first human gene, thyroglobulin, was mapped to a chromosome using cosmid clones of 
about 20 kb (Landegent et al, 1985). Improvements in software, hardware, probe 
technology, and reduced costs had a great impact on implementing the method, and 
today probes for FISH can detect areas down to 1 kb (Speicher and Carter, 2005).  
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One of the fascinating technological developments within the family of FISH methods 
is the so-called multicolor FISH. It is a whole genome screening technique using 
human chromosome painting probes to distinguish individual chromosomes. The 
spectral signature of each probe identifies the 24 different human chromosomes. 
Diverse imaging systems are available as, by way of example, M-FISH (Speicher et al, 
1996) and Spectral karyotyping (Schrock et al, 1996). The method enables a relatively 
simple way of analyzing complex karyotypic rearrangements (Lee et al, 2001, Trask, 
2002). 
Another application of the FISH techniques came in 1992 through studies made by the 
group of Kallioniemi (Kallioniemi et al, 1992). The method is called comparative 
genomic hybridization (CGH) and is based on a competitive hybridization of tumor 
and normal DNA, labeled with different colors (green and red, respectively). The 
labeled DNA is then hybridized to normal metaphases. By measuring the green-to-red 
ratio it is possible to identify imbalances present in the tumor genome. Regions 
gained/amplified in cancer will appear green, whereas regions lost will appear red. The 
resolution of this chromosomal-based approach is about 10 Mb. Even higher resolution 
is obtained using array-based CGH. The first arrays had a resolution of about 40 kb 
(Pinkel et al, 1998). In this variant of competitive hybridization, tumor and normal 
DNA targets well-characterized probes attached to a glass slide. Later technological 
improvements made it possible to reduce the probe size and increase the probe number 
so that today all known exon sequences can be evaluated in one single hybridization 
experiment (Kapur et al, 2007). The progress of FISH methods elegantly shows the 
transition from classical cytogenetics to molecular analyses. 
FISH with locus-specific probes derived from bacterial artificial chromosomes  
DNA constructs of various sizes can be transfected to bacteria that function as stable 
vectors. Bacterial artificial chromosomes (BACs) are such constructs of unique 
sequences of about 150-300 kb in size (Shizuya et al, 1992). The BAC clones 
commercially available are either end-sequenced or fully sequenced. Clones mapping 
to the region of interest can easily be identified using different databases such as the 
UCSC Genome Browser (available at http://genome.ucsc.edu/). The BACs used in this 
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thesis were retrieved from the RPCI-11 library (Osoegawa et al, 2001) and the 
CalTech human BAC library (https://bacpac.chori.org/). As several genes can map 
within one BAC clone, the discrimination among them can be performed by FISH 
using smaller fosmid clones (Kim et al, 1992). After culturing of BAC and/or fosmid 
clones on an agar plate including antibiotics (the host bacteria have an antibiotic-
resistant insert), the plasmids can be extracted by lysis of the bacterial cell membrane 
and separation of proteins and bacterial DNA. To label the extracted DNA, we used 
nick translation (Rigby et al, 1977), a technique whereby a fraction of the dNTPs in 
the DNA target strand is substituted with fluorescently marked nucleotides using 
DNAse and DNA polymerase 1. Denaturation of the slide and probe can be done 
either by heat or using chemicals such as formamide. After denaturation of both probe 
and target DNA on the slide, the probe will anneal to its target sequence because of its 
presence in higher numbers. After incubation in a humid chamber, a series of washes 
remove unspecific hybridization and slides are counterstained, typically using 4',6-
diamidino-2-phenylindole (DAPI). The result of the hybridization is evaluated using a 
fluorescent microscope (Figure 4). 
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Figure 4: Overview of the FISH workflow 
Metaphase FISH 
The location of locus-specific FISH probes can be determined looking at only one 
metaphase. In a normal diploid cell, two signals will appear using a locus-specific 
probe. If a chromosomal break occurs in the sequence covered by the probe, three 
signals will be detected, one from the normal chromosome and one from each of the 
derivative chromosomes corresponding to a splitting of the second signal. In this 
manner, candidate genes involved in translocations can be detected by FISH. 
However, if the break occurs close to the end of the probe sequence, the extra signal 
might be too small to be detected. Metaphase FISH requires cell culturing and is 
dependent of the growth of malignant cells in vitro. If an aberration is recognized by 
karyotyping and material is sparse, it is possible to destain the very same slide and 
utilize it for FISH (Teixeira et al, 2000, Micci et al, 2002). Repeated hybridizations to 
the same slide testing different BAC probes are also possible (Epstein et al, 1995).  
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Interphase FISH 
FISH experiments performed on interphase cells do not require cell culturing which 
may at times be a major advantage. FISH can then be performed on paraffin embedded 
material (Werner et al, 1997). Interphase FISH (IP-FISH) is often used for the 
detection of numerical aberrations as well as amplifications of suspected targets 
(Speicher and Carter, 2005). Commercially available kits exist for leukemias and solid 
tumors that can detect the most common aberrations. Because many cells are 
examined, this method can detect low numbers of genetically distinct subclones 
(Raimondi, 2000, Teixeira, 2002). But since the technique may be prone to false 
positive and/or false negative results, it is recommended to count a large number of 
nuclei and to test the specificity of the probe on a normal slide. In our laboratory, 
signals from 200 nuclei are counted by two independent observers and an abnormal 
signal pattern present in >10 % of cells is considered significant (Brandal et al, 2004). 
The probe design can reduce the number of false positive signals, for example by 
designing a double fusion probe. IP-FISH is, however, not suitable for breakpoint 
detection because of its inability to determine the precise probe localization.  
Some limitations in the use of FISH on cancer cell preparations must be pointed out. 
Unspecific hybridization to both intrachromosomal and extrachromosomal areas may 
in some instances resemble specific hybridization and confuse the researcher. This 
limitation must be kept in mind especially when interpreting IP-FISH results. To 
overcome this problem, the procedure should be optimized and control tests performed 
in order to get reliable results. Prior to hybridization experiments, the target slides 
must be treated to remove proteins and other components that could interfere with 
probe hybridization.  
Molecular methods for identifying and characterizing breakpoint regions 
The minimal size of a FISH probe in regular fluorescence microscopy is about 40 kb. 
This resolution level is sufficient to identify genes involved in a rearrangement, but 
does not shed light on which parts of the genes are involved. To analyze in detail the 
breakpoint position, one has to resort to molecular methods. All methods described 
below are, to some extent, based on the polymerase chain reaction (PCR), first 
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described in a clinical setting by Saiki (Saiki et al, 1985) after its development by Kary 
Mullis (Bartlett and Stirling, 2003). The wide implementation of this method has 
revolutionized analyses in molecular biology. The PCR reaction is a method for 
amplifying double stranded DNA using sequential heating and cooling steps. Key 
elements in the reaction are primers, DNA polymerase, and nucleotides. Selective and 
repeated amplification is enabled by the sequence specific primers and the tolerance of 
the polymerase enzyme of high temperatures. The procedure continues in an 
exponential fashion using the newly formed DNA as template. The two used PCR 
primers are oriented in opposite directions and typically amplify a fragment of about 
500-600 bp. In cases with a low number of target templates, a modified version of the 
PCR reaction called nested PCR can be applied. In this protocol, the sensitivity of the 
reaction is increased by running a second PCR with primers placed within the ones 
previously used. The procedure can be helpful in detecting rare mutations in a 
heterogeneous cell population. PCR based methods are extremely sensitive, therefore 
great care must be taken to avoid DNA contamination. PCR reactions searching for 
rare fusion genes are, however, less likely to produce false positives because of the 
rarity of the fusion genes we look for. Nonspecific binding of the primers to DNA or 
RNA can yield unspecific bands on PCR. To avoid this problem, careful primer design 
is important. The primers should among other factors be unique in the genome, should 
not tend to form secondary structures and the primer set should have a similar melting 
point (Sambrook and Russel, 2001).  
Long-distance PCR 
Under standard PCR reaction conditions, fragments up to two kb are amplified 
(Sambrook and Russel, 2001). Using modifications of the PCR protocol, genomic 
areas of up to 35 kb can be amplified (Barnes, 1994). To enable the synthesis of such 
long products, optimization of extension time, primer design, buffers, template quality, 
and the performance of the polymerase is necessary to obtain a good result. Given two 
candidate genes likely to take part in a translocation, long-distance PCR (LD-PCR) 
can be a good procedure to detect fusion genes, run with genomic DNA as the 
template. Primers are designed for each gene/exon and, if successful, the fusion gene is 
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amplified. If no bands occur, no information is obtained about the location of the 
rearrangement. Therefore, this method requires a clear idea as to where the breakpoints 
are situated. 
Rapid amplification of cDNA ends  
Rapid amplification of cDNA ends (RACE-PCR) can be applied if RNA is available 
and one of the fusion partners is identified. This method enables amplification of the 
3`end of an mRNA transcript, and can thereby identify the second, previously 
unknown fusion partner. Using this method, only 23-25 base pairs of known sequence 
are necessary to run a PCR amplifying also the 3`end of the potential fusion partner. 
The method takes advantage of the construction of human mRNAs. These consist of 
the coding sequence followed by a poly-A tail (Scotto-Lavino et al, 2006a). Briefly, 
cDNA sequence is generated by reverse transcription of mRNA. The primer used 
targets the poly A tail and is universal for all mRNAs. In a second round of PCR, a 
gene–specific primer mapping to the gene of interest is used to amplify the target 
sequence. A nested primer located further downstream can give more specific products 
in a new PCR. The obtained PCR product is then sequenced and alignment with the 
reference genome identifies the unknown sequence. 5`end RACE is somewhat more 
complicated and requires modifications of the protocol because the Poly A tail cannot 
be used as template (Sambrook and Russell, 2001, Scotto-Lavino et al, 2006b). As the 
poly A tail is often destroyed during RNA degradation, RACE PCR requires RNA of 
good quality. 
Quantitative PCR 
In order to establish the expression level of an mRNA transcript, quantitative PCR 
(qPCR) is today the most frequently used and generally preferred method among 
researchers/molecular laboratories. The procedure is composed of three steps: (1) the 
conversion of RNA to cDNA using reverse transcriptase, (2) amplification of the 
cDNA template in a PCR reaction, and (3) detection of amplified products in real-time 
(Gibson et al, 1996). The method differs from conventional PCR by monitoring the 
amplification process whereas in conventional PCR only the end result is analyzed. 
There are currently two ways to follow the amplification process, both of which 
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measure increases in fluorescence. The TaqMan method (Livak et al, 1995) utilizes 
specifically labeled primer probes that, when binding to their target sequence, emit a 
fluorescence signal. The increase in target sequences as the PCR progresses results in 
intensified emission. The other systems use a more unselective probe that binds all 
double stranded DNA (for example, SYBR Green®), and a rise in DNA results in 
increased emission. Unselective amplification, for example from primer-dimer 
formation, is more problematic with this approach.  
Possible pitfalls to qPCR are manifold and must be avoided from the very beginning, 
even before the sample is loaded on the qPCR instrument. Incorrect handling of the 
tumor tissue after it is removed from the human body can greatly impact the 
expression levels of the mRNAs. The RNA should be of good quality and, if more 
samples are compared, should be of similar quality. Unequal quantities of tumor cells 
in each sample may affect the expression levels of cancer specific genes. The method 
for RNA quality measurement should be equal for all samples as estimates of quality 
can differ from method to method. Furthermore, care must be taken when designing 
primers for an experiment. Traditionally, primers overlapping on one or two exons 
have been used as an expression level for the whole gene (Bustin et al, 2009). This can 
be problematic as most human genes can be alternatively spliced (de la Grange et al, 
2007). Also, using sequence from only one exon may detect contaminating DNA. It is 
therefore recommended to use primers overlapping at least 2 exons (Bustin et al, 
2009). Choosing controls for normalization is a challenging task. For a reference gene 
to be suitable for normalization, it should be expressed at a similar level across all 
samples analyzed, and must not be affected by the experimental conditions. The last 
step in the qPCR is data analysis, which is also very important. Spurious differences 
can occur if researches use different algorithms to interpret the data. Two main 
methods are used: absolute and relative quantification.  
Sequencing 
Since the 1970s, Sanger sequencing (Sanger et al, 1977) has been used to determine 
the order of bases in a given DNA fragment. The method consists of three main steps. 
First, the DNA fragment must be amplified, either by cloning into a high-copy-number 
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plasmid, or with primers in a PCR reaction. Then, cycles of template denaturation, 
primer annealing, and primer extension are carried out. This process resembles the 
PCR reaction apart for one important step: in addition to normal nucleotides, 
fluorescently labeled dideoxynucleotides are added to the reaction. Incorporation of 
these analogues results in a premature stop of the amplification process, and the 
resulting reaction mix will contain fragments of various lengths. By electrophoretic 
separation of the single-stranded end products, the sequence can be determined based 
on its emission spectrum. Sanger sequencing is applicable with DNA sequences up to 
about 1000 bases.  
Since 2005, “next generation sequencing” has emerged and provides a faster and 
cheaper sequencing technology than the Sanger method. Advances in technology 
include improvements of the initial cloning step and simultaneous detection of 
numerous DNA fragments (Shendure and Ji, 2008). The technology is still evolving, 
and promising methods based on microchips reduce costs further. One of the main 
challenges using these new technologies is processing of the enormous amount of data 
generated (Shendure and Ji, 2008). This issue does not only apply to analysis of the 
data and storage capacity, but one also has to protect patient confidentiality in a safe 
way. In addition, the newer technologies yield shorter sequence reads, with lower 
accuracy than Sanger sequencing. Several applications for next-generation sequencing 
have emerged. Planning a given study, the approach chosen should reflect its aim. 
Sequencing platforms exist for genome-wide DNA studies, RNA studies, and targeted 
areas of the genome (Shendure and Lieberman Aiden, 2012). “High throughput”, 
“long-read” and “bench top” instruments allow the researcher to choose between 
different costs and quality of the data obtained.  
Transcriptome sequencing 
The transcriptome is the complete set of transcripts of a cell, and RNA sequencing 
(RNA-seq) is a technique that analyzes the transcriptome through deep-sequencing 
(Wang et al, 2009). The first step in RNA sequencing after isolation of total RNA is 
construction of a cDNA library using mRNA as a template. mRNA must be isolated 
from the other RNA components (such as rRNA, tRNA siRNA, and miRNA). 
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Following purification, mRNA is fragmented and converted to single stranded cDNA. 
After second strand synthesis, the fragments are ligated using specific adapters 
enabling PCR amplification to a cDNA library. This library can then be sequenced 
using next generation sequencing.  
After high quality reads have been obtained from sequencing of the cDNA, the reads 
must be aligned to a reference sequence for analysis and interpretation. Different 
algorithms for analysis have been developed for various purposes. We have used two 
algorithms for fusion gene detection in the studies described in this thesis, deFuse 
(McPherson et al, 2011) and FusionMap (Ge et al, 2011), but several others are 
available (Carrara et al, 2013). As the cost of conducting RNA-seq experiments is 
declining, the method quickly becomes more widely applicable. 
Several challenges and limitations yet to be solved must be kept in mind when 
conducting and interpreting data from RNA-seq experiments. The RNA obtained 
reflects a defined moment in the cell cycle and is tissue specific. The data will 
represent RNA from all the cells analyzed, not just the tumor parenchyma cells. Also, 
no consensus exists as to which tissue is appropriate as “normal” tissue for 
comparison. In addition, all the steps in the experimental procedure are susceptible to 
errors. 
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Figure 5: Fusion gene discovery from RNA-seq datasets. In principle, three different 
possibilities for alignment exist when the reads obtained by sequencing are compared 
to the reference genome: mapping reads (1), partly aligned reads (2) and non-mapping 
reads (3). Potential fusion genes are found in the second group, but additional filtering 
and validation are necessary for fusion gene detection. Modified from Maher et al 
(2009) 
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Aims  
General aims  
The study of chromosome changes in cancer cells has since the introduction of 
banding techniques in the 1970s (Caspersson et al, 1968, Smeets, 2004) provided 
many insights into the pathogenetic processes underlying tumorigenesis. Through 
persistent characterization of the breakpoints of cancer-specific chromosomal 
rearrangements, numerous new genes involved in human malignancies have been 
identified (Mitelman et al, 2007). At times, the complexity of acquired chromosomal 
changes is almost overwhelming, especially tumors of epithelial origin tend to display 
complex karyotypes (Heim and Mitelman, 2009). However, using the screening 
technique provided by cytogenetics, one can occasionally identify relatively simple but 
nonrandomly occurring chromosomal changes which are likely to influence cancer 
development. Further characterization of these changes using molecular cytogenetic 
and strictly molecular methods may reveal further molecular details. The translational 
strategy combining research efforts applied to acquired chromosomal rearrangements 
detected during diagnostic analyses of neoplastic cells has proven successful in 
detecting new cancer-specific chromosomal aberrations. From the regular diagnostic 
services provided by the Section for Cancer Cytogenetics, we have exclusive access to 
a large number of karyotypically characterized tumor samples of different origin, 
samples that show a variety of chromosomal aberrations.  
The aim of the present thesis was to examine in detail such balanced chromosomal 
rearrangements detected in neoplastic cells and further characterize their consequences 
at the genomic level. Our aim was not to screen all patients within a disease entity, but 
rather to describe the pathogenetic events resulting from a few selected chromosomal 
aberrations that probably define a small subset of patients, and thereby elucidate an 
alternative way to cancer development. For that purpose we applied FISH and PCR 
based methods as well as transcriptome sequencing in the last two papers. These 
methods were used in different combinations to gain a complete overview of the 
genomic rearrangements and to identify their products at the RNA level. By means of 
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this multimodal approach, we could circumvent some of the limitations particular to 
each technique.  
Today, most tumor classification systems are based on the morphologic appearance of 
the tumor cells and their tissue organization as it appears through the microscope. We 
hope that our findings will help identify additional diagnostic markers that can 
distinguish tumors based on their acquired mutations, as such a classification may 
reflect important tumor characteristics better than do their histological appearance 
(Brandal et al, 2010). Eventually, our hope is that a more profound understanding of 
disease-causing mutations will reveal new targets for specific treatments. 
Additional specific aims and the theoretical rationale for each case studied are 
described in the paragraph dealing with each paper. 
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Specific aims 
Paper I 
Cytogenetic findings are crucial both for the diagnosis and prognosis of ALL patients 
(Group Francais de Cytogenetique Hematologique, 1996, Faderl et al, 1998, Harrison, 
2009). The great majority of patients with this disease have cytogenetic abnormalities 
in their bone marrow cells, with detailed analysis that includes IP-FISH examination 
having demonstrated aberrations in up to 90% of newly diagnosed ALL cases 
(Harrison et al, 2005, Moorman et al, 2007). Up to 30% of ALLs have cytogenetic 
changes leading to fusion genes (Mitelman et al, 2007) with the type of fusion varying 
across age groups. In childhood ALL, the most common rearrangements are 
hyperdiploidy, followed by a t(12;21) recombining the genes ETV6 and RUNX1 
(Moorman, 2012).  
Prognosis in ALL is highly dependent on the leukemic karyotype at disease debut. An 
example is the group of patients with a high-hyperdiploid karyotype which 
corresponds to a favorable risk profile with nearly all patients surviving if treated 
adequately (Harrison, 2011). In contrast, patients with a low-hypodiploid karyotype 
have a far worse prognosis, one study measured event-free survival after three years of 
follow-up to only 29% in this group (Harrison et al, 2004). Examples of prognostic 
differences also exist among patients with structural rearrangements; patients with 
t(12;21) have an overall favorable prognosis while t(9;22) is associated with a poor 
prognosis necessitating allogeneic stem-cell transplantation in the first complete 
remission for these patients (Pui and Evans, 2006). Several other groups based on 
recurrent aberrations are acknowledged, but because of few reported cases, many of 
the cytogenetic aberrations in ALL are of unknown prognostic significance. 
A 19-year-old patient diagnosed with B-precursor ALL was treated at our hospital. 
The cytogenetic analysis of his bone marrow aspirate revealed a 12;17-translocation as 
the sole karyotypic abnormality in the leukemic cells. The t(12;17)(p13;q12) is rare 
and of uncertain prognostic significance, but the reported data suggest a relatively 
good prognosis. Prior to our study, only 25 patients with this translocation had been 
reported, and in six of these, a fusion gene TAF15-ZNF384 had been identified 
Aims 
39 
 
(Martini et al, 2002, La Starza et al, 2005). Our aim was to investigate in molecular 
detail the consequences of the t(12;17). Were the same genes involved in our case? If 
so, was the breakpoint identical at the molecular level, i.e., were the same exons or 
introns involved? Was the fusion gene translated to an RNA transcript? Were there 
any cryptic rearrangements involved? Furthermore, we identified another ALL patient 
in our archive with a complex karyotype which included a similar t(12;17). We 
therefore examined also this second translocation addressing the questions mentioned 
above.  
Paper II 
AML is the most thoroughly studied malignancy in terms of cytogenetic aberrations 
with 16.998 cases (as of August 2013) reported in the Mitelman Database (Mitelman 
et al, 2013). The number of identified fusion genes in this disease is high and 
increasing. Roughly 60 % of patients with de novo AML display cytogenetic changes 
detectable by chromosome banding methods (Grimwade et al, 2010). In one series of 
young adult patients, the most common aberrations were trisomy 8, monosomy 7, 
t(8;21), and t(15;17) (Grimwade et al, 2010). As in ALL, the frequency of the 
aberrations depends on which age groups are examined. One of the characteristics of 
AML is that it is a heterogeneous disease. Numerous balanced translocations in 
addition to the ones mentioned above have been detected, only some of which carry a 
known diagnostic or prognostic impact (Heim and Mitelman, 2009). In addition to 
recognized cytogenetic subgroups, a panel of genes is found to be associated with 
prognosis if altered (for overview, see Gianfelici et al (Gianfelici et al, 2012)). 
A 28-year-old patient with AML was admitted to his local hospital, and a bone 
marrow aspirate was sent to our laboratory for cytogenetic examination. The G-
banding analysis revealed a t(12;13)(q14;q31) as the sole karyotypic change. We 
wanted to characterize the breakpoints in detail and determine the underlying gene-
level changes. Which were the genes involved? Was there a fusion gene resulting from 
the rearrangement or is a deregulation of gene(s) the result of the translocation? What 
was the translocation product(s) at the RNA level? Was one of the well known cancer-
related genes MDM2 and/or HMGA2, both of which map to 12q14, involved? Or were 
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genes mapping to the 13q31 area crucially involved, for example the GPC5 gene 
known to be amplified in selected cases of rhabdomyosarcoma (Williamson et al, 
2007)? 
Paper III 
Mesenchymal chondrosarcoma (MC) is a rare subtype of chondrosarcoma (<3% of 
primary chondrosarcomas) (Fletcher et al, 2013). Most patients are middle-aged and 
most tumors arise in the craniofacial bones, the ribs or the vertebrae. A biphasic 
pattern with areas of round primitive mesenchymal cells interrupted by chondroid 
elements characterizes the tumor histologically (Nakashima et al, 1986).  
Knowledge about the pathogenetic factors responsible for MC is limited, but a fusion 
gene identified in a majority of investigated cases was recently identified (Wang et al, 
2012). The fusion joins the DNA binding domain of the HEY1 gene to the C-terminal 
transcriptional activation domain of NCOA2, and it is the fourth fusion gene involving 
NCOA2 identified in human cancer (Wang et al, 2012). The fusion was identified 
using a genome-wide exon based expression array and no karyotypic information 
about the tumors was provided. The authors suggested the rearrangement to be caused 
by a submicroscopic deletion on chromosome 8.  
No consistent cytogenetic findings were described in the ten karyotyped cases of MC 
in the Mitelman database (Mitelman et al, 2013). Most karyotypes were complex. In 
two tumors, a Robertsonian translocation between chromosomes 13 and 21 was 
detected in addition to loss of all or a portion of chromosomes 8 and 20 and gain of all 
or a portion of chromosome 12 (Naumann et al, 2002). Only two previous cases with a 
simple karyotype were reported, one with trisomy 8 as the sole aberration (47,XX,+8) 
(Gatter et al, 2005), the other with a balanced t(4;19) (46,XY,t(4;19)(q35;q13)) 
(Richkind et al, 1996).  
We analyzed tumor cells from a 63-year-old woman with an MC harboring a 1;5-
translocation as the sole aberration identified at the cytogenetic level. Since the 
translocation was present in all cells cytogenetically analyzed, we karyotyped also 
cells from a peripheral blood sample to rule out the possibility of a rare constitutional 
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variant. Once we had established that the 1;5-translocation was indeed tumor specific, 
we decided to characterize this new aberration at the molecular level. Did the MC 
under examination perhaps harbor a submicroscopic deletion of chromosome 8 leading 
to the HEY1-NCOA2, the fusion gene published as typical of MC while we were 
working on our case? If so, would the putative deletion lead to the same fusion that 
had already been reported or would it result in a variant? If not, did the present tumor 
rearrangement lead to a totally different fusion gene? If a novel fusion existed, what 
was its result at the molecular level? What was the prevalence of this/these fusion 
genes in other MCs? 
Paper IV 
Pure erythroid leukemia is characterized by neoplastic proliferation of cells resembling 
proerythroblasts (Swerdlow, 2008). The disease is extremely rare and is recognized as 
a diagnostic entity together with erythroleukemia (erythroid/myeloid) under the term 
“acute erythroid leukemias” in the WHO classification system (Swerdlow, 2008). 
Differential diagnosis against megakaryoblastic leukemia may be challenging, 
especially in cases of pure erythroid leukemia without erythroid maturation. There is 
sometimes gradual progression from myelodysplasia with erythroid dysplasia to pure 
erythroid leukemia, and a diagnostic marker is needed (Domingo-Claros et al, 2002). 
The patients often follow a rapid clinical course even with the best current treatment.  
Previous cytogenetic studies of patients with erythroleukemia have displayed 
numerical and structural aberrations resembling those seen in AML in general, 
especially trisomy 8 and structural changes leading to loss of material from 
chromosomes 5 and 7 (Mitelman et al, 2013).  
An 18-month-old boy was admitted to our hospital and diagnosed with pure erythroid 
leukemia. G-banding analysis showed a karyotype interpreted as 
46,XY,der(1)t(1;1)(p31;q21),t(1;16)(p31;q24). Extensive FISH studies revealed that 
the CBFA2T3 gene was rearranged in the 1;16-translocation (Micci et al, 2011). 
However, because the material available for molecular analysis was degraded, we 
were not able to determine the leukemogenic mechanism whether it be the generation 
of a fusion gene with CBFA2T3 as one of the participants or loss of tumor suppressor 
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activity, in which case KANK1or L1TD1 could be the target since both these genes 
were found to be homozygously deleted. Furthermore, it looked as if the 1;16-
translocation is recurrent in pure erythroid leukemia since two additional cases have 
been reported with the same rearrangement (Koller et al, 1989, Castaneda et al, 1991). 
A few months after the first publication (Micci et al., 2011), we got hold of an 
additional 2 ml of coagulated blood with 3% leukemic cells from the patient. Since the 
technology in the field of sequencing had developed so fast, we decided to extract 
RNA from the sample and try high-throughput sequencing analysis. 
Our aim was now to characterize the t(1;16) at the molecular level. Would it be 
possible to identify the putative fusion gene using high throughput RNA sequencing 
working from a specimen with such a small number of abnormal cells? Was there a 
fusion gene between chromosomes 1 and 16? If so, which were the fusion partners, 
and could they be identified by PCR? What would be the possible mechanisms by 
which the chimeric protein executes its oncogenic potential? Since the FISH studies 
had identified a more complex karyotype, described as 46,XY,der(1)t(1;1)(p31;q21), 
del(1)(p11p31),der(16)t(1;16)(p31;q24), we were also wondering if the other described 
chromosomal breakpoints in the karyotype generated fusion genes. 
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Results in brief 
Paper I 
The first description of the translocation found in this case was t(12;17)(p13;q21), and 
although the most likely fusion gene was the known but rare TAF15-ZNF384 resulting 
from a t(12;17)(p13;q12), there were also several other potential candidate genes. 
ETV6 is located on 12p13 and is one of the most promiscuous gene partners in 
leukemia. To date, >30 different ETV6 partner genes have been identified (De 
Braekeleer et al, 2012, de Braekeleer et al, 2013). We used a commercially available 
ETV6/RUNX1 dual-color translocation probe to rule out the involvement of ETV6. We 
sat up a FISH-BAC assay to narrow down the breakpoints further. BAC RP11-151M4 
overlapping eight genes including the ZNF384 gene gave a split signal when 
hybridized to patient metaphase cells. We then used fosmid clones to determine the 
breakpoint with greater precision. This latter approach did not succeed, probably due 
to repeated hybridizations to the same slide, and gave too weak signals to interpret. 
Meanwhile, we identified a splitting BAC overlapping the TAF15 gene on 17q12. Our 
results so far pointed to the fusion gene TAF15-ZNF384 and the karyotype was 
reinterpreted as t(12;17)(p13;q12). Both BACs covered an area of about 150 kb. This 
is a large area to analyze at the molecular level and would require many PCR reactions 
since we did not know where the precise breakpoint was. We assumed that the 
breakpoints were the same as those detected by Martini et al. (2002), and therefore use 
the same primers. We successfully amplified a TAF15-ZNF384 fragment. 
We then wanted to investigate whether the TAF15-ZNF384 was present also in the 
second ALL patient identified through a search of our patient archives. FISH and PCR 
experiments confirmed the presence of a TAF15-ZNF384 fusion from DNA extracted 
from the leukemic cells also in that case.  
Sanger sequencing of the PCR products from the two cases demonstrated that the 
break in TAF15 had occurred within intron nine in the first patient and within intron 
six in the second patient. In the ZNF384 gene, the break occurred within intron two in 
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both cases. Only in patient 1 was RNA available, and the transcript could be 
confirmed. 
Paper II 
To characterize the breakpoint position of the t(12;13) we began with FISH using 
specific BAC clones. Since we had no putative fusion genes for this case, we scattered 
the probes in chromosomal bands 12q14-q21, an area of approximately 20 Mb (UCSC 
Genome Browser (Kent et al, 2002). In total, 36 BAC probes were tested before two 
splitting probes (one on the derivative chromosome 12 and one on the derivative 
chromosome 13) were identified. On chromosomal band 12q14 a split signal was seen 
using a BAC which overlaps the HMGA2 gene. Fosmid clones were used to narrow 
down the breakpoint, and we were able to map it to the 3`end of the gene. The 
breakpoint on chromosomal band 13q31 was found to be in a region where no known 
genes are located. A fusion gene was therefore an unlikely consequence of this 
translocation. Attempts to amplify the breakpoint region on genomic DNA were 
unsuccessful, so in order to describe the precise rearrangement, we ran a RACE PCR 
amplifying the 5`end of HMGA2. We identified a truncated form of HMGA2 by 
sequencing the resulting transcript. To demonstrate that the truncated transcript had 
consequences also at the RNA and protein level, we wanted to quantify the expression 
of HMGA2 by qPCR and immunohistochemistry. HMGA2 expression was 
considerable increased compared to a control group of AML patients assed by qPCR. 
Increased expression of HMGA2 was also demonstrated at the protein level, as we by 
immunohistochemistry saw specific staining of the blast cell nuclei.  
Paper III 
Having identified an MC patient with a tumor-specific t(1;5), we searched for 
additional patients within the Sarcoma Registry at the Norwegian Radium Hospital to 
find patients with the same diagnosis. From 1986 to 2010 only 3 such patients were 
identified, underlining the rarity of these tumors. We got hold of frozen material from 
all three tumors, and run a reverse transcriptase PCR aiming to amplify the HEY1-
NCOA2 fusion using the same primers as used by Wang et al (2012). A PCR fragment 
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was amplified in all but the t(1;5) case, and subsequent Sanger sequencing confirmed 
the presence of a HEY1-NCOA2 transcript in the other tumors.   
The splitting BAC on 5q33 overlapped four genes. Using fosmid clones we narrowed 
the area further, to the genes PDGFRβ and CDX1. Transcriptome sequencing was 
performed and the “deFuse” algorithm (McPherson et al, 2011) was used to align 
sequences and predict potential fusion genes. 
The list of predicted fusion genes exceeded 100. We focused on putative fusions 
between chromosomes 1 and 5, as we knew these two chromosomes were rearranged. 
A putative IRF2BP2-CDX1transcript topped the list of potential fusions when ranked 
by split count, i.e., the number of reads supporting the prediction. The IRF2BP2-CDX1 
was validated using primers outside the predicted transcript, and was also detected on 
genomic DNA extracted from the tumor. The fusion was not identified in any of the 
other described cases.  
Paper IV 
The blood sample from the patient harboring the t(1;16) contained 3% leukemic cells. 
RNA was extracted and sent for sequencing. A total of 107 million reads were 
obtained. The filtered data were run through the Fusion Map software (Ge et al, 2011), 
and a list with about 500 putative fusion genes was identified. As number ten in this 
list ordered by the number of reads supporting the predicted fusion, a fusion between 
the genes CBFA2T3 and NFIA was identified. These genes map to chromosome bands 
16q24 and 1p31, respectively, which fits well with the described karyotype and the 
previous FISH results. The NFIA/CBFA2T3 fusion was verified by PCR and 
subsequent Sanger sequencing. As the FISH studies had revealed that the t(1;16) was 
in fact more complex than originally thought, in silico analysis was performed of the 
sequences that involved chromosome 1. All predicted transcripts contained repetitive 
sequences or sequences with a high sequence identity to other genes, making them 
unlikely fusion partners.  
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The fusion gene gave an open reading frame and was predicted to encode a protein 
consisting of 811 amino acids, combining 208 amino-acid residues from NFIA and 603 
residues from CBFA2T3. 
 
Discussion 
 
47 
 
Discussion 
Methodological considerations  
In this section, I shall discuss the study design of the subprojects that form the basis 
for this thesis in addition to some aspects of the methods applied. General aspects of 
each of the utilized method were discussed in the Introduction.  
Study design 
In all the studies presented in this thesis, only one or a few patient samples were 
examined. The selected cases were those with rare, cancer-specific cytogenetic 
aberrations, all identified through our diagnostic service. It is unquestionable that case 
reports and small series cannot replace well-designed, statistically-oriented studies 
when focusing on a particular therapy or the efficiency of a certain diagnostic test. 
However, they can be equally important when aimed in the right direction 
(Vandenbroucke, 2001). Case studies have historically provided significant advances 
also in cancer research. The famous BCR-ABL story started with the identification of a 
minute chromosome in cells from two patients with chronic leukemia (Nowell and 
Hungerford, 1960a). Nowadays, single-patient studies are the first to be presented 
when a new technology is available, but still too expensive and time-consuming for the 
general research community. One such study was published in 2008 when the entire 
genome of a cytogenetically normal AML patient was sequenced (Ley et al, 2008). 
Unusual effects of a drug be it adverse or beneficial, are also often first reported as a 
case report. In other words, case studies are hypothesis-generating for forthcoming 
studies in the field, but cannot have statistical value or be directly implemented in 
evidence-based medicine. 
We used G-banding of chromosomal preparations as an initial screening technique to 
identify clonal chromosomal aberrations. Cytogenetic analysis is a robust technique 
that has survived the changing trends in cancer research since the correct chromosome 
number was identified in 1956 (Tjio and Levan, 1956). It offers an overview of the cell 
genome which can be directly visualized down the microscope without the need for 
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complex algorithms. Some limitations of the method must be kept in mind: dividing 
cells are required for cytogenetic analysis, and some tumor cells do not divide in vitro, 
resulting in a false negative result (i.e., a normal karyotype). This has turned out to 
apply mostly to tumors of epithelial origin (Edwards, 2010). The number of aberrant 
cells represents the neoplastic cells’ ability to divide in vitro rather than in vivo, and so 
analysis of G-banded chromosomes is not ideal to assess the relative size of a given 
tumor or leukemia clone. Also, chromosome morphology may be too poor to identify 
the karyotypic abnormalities (Mitelman et al, 2007). The cases singled out for scrutiny 
in this thesis had cells that were able to divide in vitro. Cases with balanced 
translocations (with the exception of the case studied in paper IV and of one subproject 
for which a complete molecular characterization was not obtained; see Table 2) were 
chosen because these changes most probably are important for the neoplastic 
transformation.  
Working with limited material 
Studying cases identified through the diagnostic service had some drawbacks. Material 
available for analysis was often sparse and had not been optimally collected for 
research purposes. We had no means of controlling how much tissue was left for 
analysis or for how long the tissue was stored at room temperature before freezing 
(something that affects the quality of extracted nucleic acids). The following example 
demonstrates this limitation: in paper II, where good quality RNA was available from 
the malignant cells, we were able to run a 3`RACE PCR after the FISH results 
indicated involvement of the HMGA2 gene. In contrast, the same technique was not 
feasible in the study leading to paper III due to degraded RNA. 
After karyotyping, we applied FISH-based methods whenever feasible. To meet the 
challenge of sparse material, we tried to re-use previously G-banded metaphase 
spreads for FISH analysis, an approach that has been successfully applied in our 
laboratory before (Micci et al, 2002). The advantage is that the identity of the 
chromosomes studied is known beforehand, something that makes the interpretation of 
weak signals easier. Slides can thus be used for several rounds of hybridization. The 
identification of the fusion gene TAF15-ZNF384 in paper I was made possible by this 
Discussion 
 
49 
 
approach when only two abnormal metaphases were available for analysis. However, 
more material for analysis would have been necessary had we not suspected that these 
two genes were the ones involved. The downside of re-using material is the harshness 
of the destaining protocol which wears down the biological material. Sequential 
hybridizations first remove proteins, but repeated hybridizations also reduce the DNA 
content of the chromosomes, making signal intensity weaker. Repeated hybridizations 
may also increase unspecific hybridization because of remaining debris from previous 
procedures.  
Even with these efforts to save and re-use material, four additional projects planned to 
be a part of this thesis had to be discontinued because of lack of material before a 
complete molecular characterization of the cytogenetic aberration was achieved. 
(Table 2 provides an overview). Three of these cases were sarcomas characterized by 
apparently balanced translocations. The main problem working with these cases was 
that so few metaphases were available for FISH studies. One example was the case of 
a chondrosarcoma showing a 5;10-translocation as the sole karyotypic change. In the 
20 slides dropped only four abnormal metaphases were identified. Neither in this case 
nor in any of the other sarcoma cases was the RNA quality good enough to perform 
transcriptome sequencing.  
Malignancy Chromosomal aberration 
Chondrosarcoma t(5;10)(q13;q26) 
Liposarcoma t(3;9)(p25;q22) 
Sarcoma t(2;17)(q23;q23) 
Leukemia der(9)t(9;12)(p23;q13)*  
Table 2: Projects that had to be ended because of lacking material.*Part of complex 
karyotype. 
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Locus-specific FISH  
Locus-specific FISH was used in 
papers I-III. This technique was 
crucial for our experiments before 
we implemented transcriptome 
sequencing as a tool. To determine a 
breakpoint position, clear and 
recognizable signals are necessary, 
as the staining used with FISH 
(DAPI) only displays the 
chromosome size and breakpoint 
position. From time to time we 
experienced background 
hybridization to be a problem with locus-specific FISH, especially when using old and 
destained slides (Figure 6). There were three main issues or problems with the FISH 
protocol: unspecific hybridization of the probe to the chromosomes, insufficient 
pretreatment of the slides, and poor probe quality. Addressing the first issue, we 
assessed the necessary amount of Cot-DNA. Cot-DNA is added to FISH experiments 
because it hybridizes to repetitive sequences in the genome, preventing false signals 
caused by unspecific binding (Fan, 2002). However, changing the concentration of 
Cot-DNA did not alter background signals. Next, we modified the pre and post 
hybridization washes, but with no improvement of results. Third, the prepared BAC 
probes were evaluated. When extracted from the bacterial cell, the BAC DNA is 
mixed with bacterial DNA (which exceeds BAC DNA by far), and we applied a 
different protocol to improve the BAC DNA output. Unfortunately, no consistent 
results favoring one or the other modification were obtained and troubleshooting of 
such a comprehensive protocol turned out to be a difficult task. Most likely, physical 
and/or chemical properties of the probe in combination with the slides contributed to 
the background signals.  
Figure 6: Hybridization of this probe resulted in 
both chromosomal and extrachromosomal signals, 
making interpretation difficult  
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PCR-based methods 
We used PCR-based methods to characterize the breakpoint area defined by FISH. Our 
choice of method in each case was highly dependent on the amount of available 
material.  
The genes involved in chromosomal rearrangements may contain large introns. Trying 
to amplify a hybrid gene from genomic DNA can therefore result in long PCR 
fragments, sometimes longer than the capacity of the enzymes used for the PCR 
reaction. We met this challenge by optimizing the PCR protocol for amplifying long 
fragments (LD-PCR). This variant of PCR is more susceptible to false positive PCR 
products because of its long extension time. Therefore, if a band appeared as a result 
of LD-PCR on genomic DNA, we ran more reactions involving neighboring exons. 
Whenever possible we preferred RNA as a template for RT-PCR. The “trial and error” 
approach we used when we had identified two putative genes does not work if 
unexpected submicroscopic rearrangements are present at the breakpoint position. As 
an example, the IRF2BP2-CDX1 fusion gene (paper III) would not have been easy to 
identify using this approach.  
We used qPCR in paper II to assess the expression of HMGA2. As discussed in the 
introduction, there are many pitfalls to qPCR, one being that it is difficult to select an 
appropriate control group. Not much is known about HMGA2 in hematological 
malignancies, but it seems that neoplasia-associated rearrangements involving 
chromosomal bands 12q13-15 lead to inappropriate expression of the protein (Fusco 
and Fedele, 2007). We chose to include AML patients with a common cytogenetic 
aberration, trisomy 8 (Heim and Mitelman, 2009) but without any visible changes of 
chromosome 12 and a “normal” bone marrow sample as a control group. We figured 
that comparison only with bone marrow from healthy donors could give an incorrect 
estimate of the gene expression as several genes may be aberrantly expressed in AML 
in general. We identified two AML patients with trisomy 8 as the only cytogenetic 
aberration, and one patient with monosomy 7 in addition to trisomy 8. A larger control 
group would have given us a more robust result, but the set up for this study limited us 
in this regard. As an internal control we chose the GUSB gene, a commonly used gene 
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for endogenous control in qPCR studies, and one of the genes suggested by Beillard 
and colleagues as suitable for detecting minimal residual disease in leukemia (Beillard 
et al, 2003).  
Identifying fusion genes by transcriptome sequencing 
The traditional way to identify fusion genes, the use of locus-specific FISH followed 
by PCR-based methods, was applied in papers I and II. The drawback of this approach 
is that is can be labor-intensive and requires good quality metaphases in sufficient 
number. In papers III and IV we used RNA sequencing in combination with G-
banding. This rather new method for fusion gene detection allowed us to target our 
analysis to the chromosomal aberration described cytogenetically. Identification of 
fusion genes in RNA-seq datasets was first reported in 2009 (Maher et al, 2009). 
Tanas and colleagues were the first group to implement cytogenetic methods together 
with transcriptome sequencing, thus identifying a fusion gene in epithelioid 
hemangioendothelioma (a rare vascular sarcoma) (Tanas et al, 2011). Analysis of 
transcriptome data can be challenging, but we avoid some problems by combining 
cytogenetics and sequencing. Several algorithms have been proposed for fusion gene 
detection in RNA-seq datasets, all with different biases that must be taken into 
consideration (Carrara et al, 2013). Some algorithms apply a more stringent filtering 
than others, aiming to reduce the number of false positive predictions. The risk with 
this approach is that also true transcripts may be eliminated. FusionMap (applied in 
paper IV) uses less stringent filtering than deFuse (paper III) and requires less 
computational recourses. When a putative fusion region is already identified through 
cytogenetic analysis, the problem with false positive predictions becomes less 
challenging.  
Detection of fusion genes resulting from cryptic genomic aberrations is now possible 
because of advances in genomic technologies. Through analysis of data from array-
based studies, several investigators have reported novel and recurrent gene fusions 
(Tomlins et al, 2005, Wang et al, 2012, Giacomini et al, 2013). Although such studies 
are said to be unbiased, informed choices must nonetheless be made when analyzing 
the data. The large datasets generated compel researchers to filter the data in some 
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manner, and often genes not previously linked to cancer are excluded from further 
analysis, risking elimination of pathogenically important genes.  
These different methods for identifying altered genes complement each other. The 
HEY1-NCOA2 recently detected in MCs would probably not have been identified 
cytogenetically, as it results from an interstitial deletion, while the t(1;5) if present in a 
subset of MC seems to be too rare to be identified in studies of only a few patients; it 
is probably a rare aberration in a rare cancer. 
Biological considerations 
In this thesis, three chromosomal rearrangements in acute leukemia and one 
rearrangement in an MC were investigated in molecular detail. The aims of the studies 
were descriptive, i.e., we wanted to characterize the rearranged gene(s) at the genome 
level. We also assessed the consequences at the RNA level, whenever possible. 
Why study rare cancers? 
Despite the fact that most research efforts are directed towards common malignancies 
such as cancers of the prostate, breast, lung, and colon (Cancer Registry of Norway, 
2013), we decided to study samples from some rare tumor types. We see several 
reasons why also rare cancers may be worth studying. First, in some perspectives the 
division between rare and common cancers is artificial. Molecular profiling of 
common tumors have demonstrated that they are the phenotypic outcome of numerous 
and different pathogenetic processes (Munoz and Kurzrock, 2012). Based on the 
notion that there are fewer pathways that lead to the development of rare cancers 
(Braiteh and Kurzrock, 2007), rare cancers may be more homogenous, and therefore 
easier to study. In fact, most of the successful therapies recently developed are directed 
towards rare cancers (Braiteh and Kurzrock, 2007). Occasionally, discoveries in rare 
cancer types are useful also in other, more common cancers. One example is found in 
a subgroup of lung cancers; activation of the ALK gene through a gene fusion was first 
identified in anaplastic large-cell lymphoma (Kutok and Aster, 2002). The same fusion 
gene has subsequently been identified in about 4% of non small cell lung carcinomas 
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(Soda et al, 2007), and targeted therapy inhibiting ALK is now implemented in the 
treatment of these patients (Kwak et al, 2010).  
Why study balanced translocations? 
In the “cytogenetic dictionary”, chromosomal aberrations are divided into primary and 
secondary aberrations, in addition to a third type, called cytogenetic noise (Heim and 
Mitelman, 1989). The primary aberrations are thought to be the tumor initiating 
events, i.e., necessary for cancer development. These aberrations are often found alone 
and are correlated with a distinct tumor type. Secondary aberrations, on the other hand, 
rarely exist alone and are believed to occur in cancer cells already harboring primary 
aberrations. They are important in tumor progression, and are probably selected in a 
Darwinian fashion. Cytogenetic noise is a term for non-clonal aberrations that occur 
because of genomic instability (Heim and Mitelman, 1989).  
The division into “drivers” and “passengers” is another way of categorizing mutations 
in cancer used frequently today (Stratton et al, 2009). “Driver” mutations are those 
thought to be causally implicated in oncogenesis. Passenger mutations are not believed 
to confer a growth advantage on the cell carrying them, and therefore do not contribute 
to cancer development (Stratton et al, 2009).  
Translation between these two set of terms is not always easy. Cytogenetic aberrations 
may refer to loss or gain of a whole or parts of a chromosome, while the drivers and 
passengers more often refer to single base substitutions within genes. On other 
occasions the translation is more straightforward. Balanced translocations, for 
example, are regarded as primary cytogenetic aberrations when identified as a sole 
cytogenetic change, and the fusion genes that such aberrations often form are “drivers” 
of the oncogenic process.  
We work from the premise that the simple chromosome aberrations such as those 
examined in this thesis represent primary abnormalities and/or driver mutations, 
something that makes them all the more interesting to study. Although we cannot be 
certain about their contribution to oncogenesis, several considerations, some described 
below, support this hypothesis.  
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Genes involved in transcriptional regulation and nucleic acid binding are 
overrepresented among genes involved in human malignancies (Furney et al, 2006). 
Fusion gene partners are, according to recent studies, either genes involved in 
transcriptional control or they act as tyrosine kinases (Mitelman et al, 2004). All seven 
genes identified through the chromosomal translocations studied by us as part of this 
thesis influence the transcription process. ZNF384, CDX1, HMGA2 and NFIA are all 
transcription factors and bind directly to DNA (Vaquerizas et al, 2009). TAF15 
interacts with transcription factor TBP, IRF2BP2 interacts with transcription factor 
IRF, and CBFA2T3 acts as a transcriptional repressor (Kochetkova et al, 2002). 
The fusion transcripts found in leukemias and sarcomas are often composed of parts of 
genes involved in gene regulation or chromatin-modification (Edwards, 2010). The 
fact that all the four fusion genes identified (TAF15-ZNF384, HEY1-NCOA2, 
IRF2BP2-CDX1, and NFIA-CBFA2T3) join two gene-regulating genes therefore 
supports a functional role in oncogenesis. Also, structural similarities to already well-
known fusion genes strengthen the probability of a role in cancer development. This is 
exemplified by the TAF15 gene, first identified in 2002 (Martini et al, 2002). TAF15 
belongs to the TET protein family. It is structurally similar to another, more famous 
member of the same family, specifically the Ewing sarcoma protein known from the 
childhood malignancy carrying the same name (Tan and Manley, 2009). Not 
surprisingly, EWSR1 was demonstrated to form pair with ZNF384 in other leukemia 
patients (Martini et al, 2002). Such parallels can also be drawn for the CDX1 gene that 
forms the 3`end of the IRF2BP2-CDX1gene, although less powerful. CDX2, closely 
related to CDX1, has been detected as a part of a fusion gene in leukemia (Chase et al, 
1999). Structural similarities also exist between NFIA-CBFA2T3 and other, more well-
known fusion genes, namely the RUNX1-CBFA2T3 resulting from a t(16;21) (Gamou 
et al, 1998) 
Two of the fusion genes identified in this thesis are already known to be recurrent 
(TAF15-ZNF384, HEY1-NCOA2), and this supports their role in oncogenesis. As 
mentioned above, the NFIA-CBFA2T3 fusion is also likely to be recurrent, since a 
description of two patients with erythroleukemia and a t(1;16)(p31;q24) in their 
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karyotype was reported in the Mitelman database (Koller et al, 1989, Castaneda et al, 
1991).  
In paper II we investigated a novel t(12;13) identified in a patient with AML. Instead 
of finding a new fusion gene as we had expected, we mapped the breakpoint in 12q13 
to inside the HMGA2 gene. No gene resides at the breakpoint position identified on 
chromosome 13q. This mechanism of gene alteration is not the typical consequence of 
a balanced translocation as translocations usually cause either a fusion gene or 
deregulation of one gene through juxtaposition with regulatory sequences from another 
gene (see Introduction). Deregulation of HMGA2 through 12q13~15 rearrangements is 
nevertheless well-known in benign mesenchymal tumors, lipomas in particular (Fusco 
and Fedele, 2007). The growth benefit of these tumors is suggested to be caused by a 
loss of a repressive miRNA targeting the 3` end of HMGA2 (Mayr et al, 2007). When 
overexpression of HMGA2 and the closely related HMGA1 is detected in malignant 
tumors, it seems to be correlated with a highly malignant phenotype and reduced 
survival (Fusco and Fedele, 2007). Knowledge about HMGA2’s role in hematological 
malignancies is limited, but the mechanism of deregulation seems to be similar to that 
observed in the case reported by us; HMGA2 is activated by a translocation involving 
12q, and no expressed fusion genes are identified. Hematological malignancies of 
different types have been associated with HMGA2 deregulation. (Table 3 provides an 
overview of the reported cases). 
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Author Disease Abbreviation  Results Other 
mutation 
(Aliano et al, 
2007) 
PV 
 
t(12;21)(q14;q22) 
 
FISH+ 
HMGA2 expression 
JAK2 
(Andrieux et al, 
2004) 
MMM t(4;12)(q33;q15-q21) 
t(5;12)(p14;q15-q21) 
FISH+ 
HMGA2 expression 
Truncated HMGA2 
(ex 1-4) 
NR  
(Inoue et al, 
2006) 
PNH (benign) t(12;12)(q13;q15) 
 
FISH+ 
HMGA2 expression 
(ex5/ 3`UTR) 
PIGA 
(Kottickal et al, 
1998) 
AML 
AML 
t(5;12)(q10;q10) 
t(7;12)(p22;q13), 
t(12;13)(q10;q10) 
Isoforms of 
HMGA2 detected 
NR 
(Meyer et al, 
2007) 
CML(14 pt) t(9;22) (13 pt) 
Normal (1 pt) 
HMGA2 expression 
correlated to WBC count 
BCR-ABL 
(Odero et al, 
2005) 
MDS (RAEB1) 
MDS (RAEB2) 
MDS (RAEB1) 
MDS/MPD 
MDS/MPD 
(aCML) 
Secondary MDS 
(RAEB1) 
t(7;12)(p12;q13) 
t(12;14)(q13;q31) 
t(12;12)(p11;q13)  
t(12;20)(q15;q11.2)  
t(8;12)(q22;q13) 
 
t(11;12)(q23;q15)  
 
FISH+  
HMGA2 expression 
Truncated HMGA2 
transcripts detected in 
two patients (ex 1-3 and 
ex 1-3 together with ex 
1-2).  
 
NR 
(Pierantoni et 
al, 2003) 
ALL  
 
t(9;12)(p22;q14) 
 
FISH+,  
Truncated HMGA2     
(ex 1-3) 
NR 
(Rommel et al, 
1997) 
CML (11 pt) 
AML (3 pt) 
t(9;22) 
NR 
HMGA2 expression BCR-ABL 
(Santulli et al, 
2000) 
CLL 
 
t(12;14)(q13;q32),t(9; 
13)(p13;q14) 
FISH+,  
HMGA2 expression by 
immunohistochemistry 
NR 
(Storlazzi et al, 
2006) 
PV t(3;12)(q26;q14)  
 
FISH+, 
HMGA2 (ex1-5)-TNIK 
detected but not 
expressed.  
HMGA2 expression 
NR 
Table 3: Hematological neoplasias with HMGA2 involvement. Abbreviations: PV: 
Polycytemia vera, MMM: Myelofibrosis with myeloid metaplasia, PNH: Paroxysmal 
nocturnal hematuria, MDS: Myelodysplastic syndrome, RAEB: Refractory anemia with 
excess blasts, MPD: Myeloproliferative disorder, ALL: Acute lymphoblastic leukemia, CML: 
Chronic myeloid leukemia, CLL: Chronic lymphocytic leukemia, FISH+: FISH results 
showing HMGA2 involvement, ex: exon, NR: Not reported, WBC: White blood cells, pt: 
patient 
 
Do the identified fusion genes define distinct disease subgroups? 
Fusion genes are in principal tumor type specific, and therefore constitute a useful tool 
in diagnostics (Mitelman et al, 2007). This recognition makes fusion genes important 
for pathological diagnosis in a range of hematological and mesenchymal tumors. 
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However, for most tumors, such disease specific biomarkers are absent. The MCs were 
until recently such a tumor entity lacking a distinctive marker and the diagnosis 
depended solely on histological characteristics and immunostaining (Fletcher et al, 
2013). The HEY1-NCOA2 fusion gene (Wang et al, 2012), identified while we were 
working on paper III, now comes across as such a new and specific marker. So far, 29 
cases have been analyzed, with the identification of the gene HEY1-NCOA2 in 21 of 
29 (72%) of the tested patients (Nakayama et al, 2012, Wang et al, 2012) and paper 
III. IRF2BP2-CDX1 is the second fusion gene to be identified in this tumor type and 
may constitute an alternative pathogenetic pathway. However, since it so far is 
identified in only one tumor, the IRF2BP2-CDX1 may be unique to these tumor cells. 
Also, when more than one fusion gene is identified in a sarcoma subtype, they usually 
activate the same oncogenic pathway (Tan and Manley, 2009). The rarity of MCs 
makes it difficult to investigate more tumors and thus clarify these issues.  
Translocations involving the ZNF384 gene on 12p13 (paper I) seem to define a 
subgroup of ALL patients (La Starza et al, 2005). In addition to the t(12;17), ZNF384 
is also involved in a t(12;22) and a t(12;19). The clinical characteristics of the patients 
reported by us in paper I are in accordance with previously reported cases. Patients are 
usually young adults with an initial good response to chemotherapy (La Starza et al, 
2005). However, the total number of reported cases is too small to conclude as to the 
prognostic impact of these rearrangements.  
The clinical characteristics of leukemia patients characterized cytogenetically by the 
t(1;16) examined in paper IV seem to correspond to a distinct clinical subtype. Three 
patients, including the one reported in paper IV, have so far been identified with a 
t(1;16)(p13;q24) and leukemic blasts of the erythroid lineage. They were all young 
boys and the outcome was poor.  
Is one fusion gene enough to generate a malignant cell clone? 
The oncogenic potential of the genes identified by us, relative to other possible 
mutations in the tumors examined, is difficult to assess. Most available data imply that 
more than one mutation is required to generate a malignancy (Mitelman et al, 2007). 
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On the other hand, in vitro studies of cells transfected with EWSR1-FLI1, the 
dominating fusion gene in Ewing sarcoma, showed the development of a tumor-like 
phenotype in spite of the fact that only a single oncogenic event had occurred (Riggi et 
al, 2005). The oncogenic contribution of fusion genes can also be studied in transgenic 
mouse models. Introduction of the FUS-DDIT3 fusion gene specific for liposarcoma 
into the mouse genome resulted in the development of liposarcomas resembling those 
seen in humans (Perez-Losada et al, 2000). This fusion gene seems to require a 
susceptible cell type to cause tumor growth; although the chimeric protein was 
identified in several tissues, only from adipocytes did tumors develop. The BCR-ABL 
fusion transcript of CML also seems to be sufficient to cause disease; however, 
additional genetic events are strongly correlated with disease progression (Deininger et 
al, 2000). Data also suggest that a fusion gene has to be present “at the wrong place, at 
the wrong time” in order to cause disease; BCR-ABL transcripts can be detected at low 
levels in the blood from normal individuals (Bose et al, 1998). 
In all the leukemia cases described in papers I, II and IV (except for the additional 
patient identified in our database), a scan for mutations of known leukemia-associated 
genes was performed at the Department of Pathology at our hospital. This was done as 
part of the diagnostic routine. In papers I and II, alterations of the FLT3 gene were 
identified. Point mutations in this gene are associated with a poor prognosis in AML 
patients, and usually co-exist with other oncogenic mutations (Kottaridis et al, 2001, 
Gilliland and Griffin, 2002). Newer data obtained from sequencing studies 
demonstrate that a typical solid tumor harbors 33-66 mutations expected to alter 
protein expression, while the corresponding number for pediatric tumors and 
leukemias is 9.6 mutations (Vogelstein et al, 2013). Therefore, it is entirely possible, 
perhaps even likely, that the malignancies studied by us harbored also other, not 
recognized, mutations.  
Consequences of gene alteration on protein expression 
If a fusion gene/gene mutation is identified, it can in theory be translated into a protein 
with new and oncogenic capabilities, or it can result in deregulation of one of the 
implied genes, usually overexpression (Mitelman et al, 2007). Most genes 
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characterized in this thesis were examined both at the DNA (FISH, PCR on genomic 
DNA) and the RNA (RT-PCR, qPCR and RNA-seq) level. In papers II and III, we also 
wanted to assess whether the altered genes influenced protein expression. In paper II, 
immunohistochemistry targeting HMGA2 demonstrated specific staining in blast 
nuclei. HMGA2 is not normally expressed in adult tissues (Fusco and Fedele, 2007) 
and detection by immunohistochemistry therefore implies abnormal expression of this 
protein. In paper III, CDX1 protein expression would be an indirect assessment for the 
translation of the IRF2BP2-CDX1fusion gene. CDX1 antibodies were commercially 
available, but repeated control experiments resulted in unspecific staining. Therefore, 
we were not able to evaluate if a fusion protein was formed using 
immunohistochemistry. Some assumptions about gene translation can still be made; 
using the “Open Reading Frame Finder” at NCBI both the novel fusion transcripts 
IRF2BP2-CDX1 and NFIA-CBFA2T3 were predicted to give an open reading frame 
(http://www.ncbi.nlm.nih.gov/projects/gorf/), supporting the notion that these fusion 
genes are translated into a protein.  
The TAF15-ZNF384 gene has been functionally evaluated before; the fusion showed 
transforming properties in a cell assay (Martini et al, 2002). From time to time, 
however, a balanced translocation can result in a truncated mRNA transcript, either 
due to a preterm stop codon in the coding sequence or a missense mutation resulting in 
an mRNA with altered protein-generating capabilities. This consequence can also be 
of pathogenetic importance if affecting a tumor suppressor gene. A wide range of 
methods exists to assess the functional significance of gene fusions. Some of these are 
exemplified in Table 4. Cell assays would be a natural starting point if one were to 
examine the fusion genes identified by us at the protein level. 
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Setting Study subject End point Requirements Example study 
In vitro Cell lines Cell viability Tumor cells/cell line 
expression the fusion 
gene in question 
Giacomini et al, 
(2013) 
  Cell proliferation    
  Cell invasion    
  Cell transforming properties  Maritini et al, 
(2002) 
In vivo Transgenic mice Tumor 
formation/development of 
characteristic tumors 
A viable transgenic 
mouse model 
Perez-Losada et 
al, (2000) 
  Disease-specific survival    
In vivo Human beings 
(Phase I study)  
Progression free survival Patients harboring the 
fusion gene in question 
and a small molecule 
inhibitor targeting it 
Kwak et al, 
(2010) 
Table 4: Examples of methods for evaluation of the oncogenic contribution of a fusion 
gene 
The structure of breakpoints and the fusion genes they cause  
We have described in detail the breakpoints, the involved genes, and the fusion 
transcripts identified. By similar descriptions also in future cases, it can be clarified 
which parts of the involved genes account for the oncogenic potential. This knowledge 
can be essential if a potential interfering molecule is identified. One fusion gene can 
also exist in slightly different versions, i.e., involving different exons from the 
involved genes. This may again lead to fusion proteins with different transcriptional 
activities that again affect tumor phenotype, progression and prognosis (Zoubek et al, 
1996, de Alava et al, 1998, Gonzalez et al, 2007). The TAF15-ZNF384 fusion had 
been identified in two different versions before, one containing exons 1-9 of TAF15 
and the other exons 1-6, both fused to exon 3 of ZNF384 (Martini et al, 2002). We 
confirmed these two fusion gene variants that exons 1-6 of TAF15 are sufficient for 
development of the disease. Potential prognostic differences caused by these two 
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TAF15-ZNF384 transcripts are impossible to assess due to the low number of patients 
reported.  
The breakpoint region of the HEY1-NCOA2 fusion was identical in our study (paper 
III) and all other analyzed cases (Wang et al, 2012). Future analyses of the IRF2BP2-
CDX1 and NFIA-CBFA2T3 genes will reveal if different variants exist for these 
fusions. 
In paper III, we expected that a balanced translocation had occurred between 
chromosomes 1 and 5. However, due to the orientation of the involved genes 
(IRF2BP2 and CDX1), some additional rearrangement must have taken place. We tried 
to investigate this issue further by locus-specific FISH overlapping the breakpoint 
position on chromosome band 1q42. We validated IRF2BP2 as one of the fusion 
partners and expected a BAC probe overlapping IRF2BP2 to yield a split signal. 
Instead, we saw two signals located on chromosome 1. We concluded that a 
submicroscopic rearrangement must have taken place, but were not able to 
characterize the rearrangement further.  
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Conclusions and future perspectives 
In the papers presented in this thesis we have described the molecular consequences of 
four different cytogenetic aberrations in malignant cells. This has resulted in better 
characterization of two infrequent aberrations whose gene-level consequences were 
already known, and the detection of two new cancer-specific fusion genes.  
The aim of cancer research should ultimately be to reduce the mortality and morbidity 
associated with cancer. There are many ways in which this goal can be attained. Our 
work may first have an impact diagnostically, as numerous genetic aberrations have 
been demonstrated to be disease specific (Mitelman et al, 2007). Improved diagnostics 
would contribute to better cancer treatment, by selection of the right patients for the 
right treatment. Stratifying patients on the basis of genetic aberrations is already 
implemented for the most common hematological neoplasias, and has resulted in 
differences in treatment protocols based on the known prognostic impact of certain 
aberrations (Swerdlow, 2008).  
Our group has for many years studied such changes and the research continues. With 
the recent introduction of transcriptome sequencing, the group has so far published 
four articles in addition to papers III and IV using transcriptome sequencing to identify 
fusion genes (Panagopoulos et al, 2012, Panagopoulos et al, 2013a, Panagopoulos et 
al, 2013b, Panagopoulos et al, 2013c). Even though these studies for the most part 
were of single cases, we expect to broaden them in the future. To generate more 
knowledge and understanding, gene fusions should be examined in larger cohorts of 
patients with malignant diseases, preferably with the same cytogenetic characteristics, 
to determine their prevalence and specificity as biomarkers. For HMGA2, the gene we 
found to be deregulated in AML in paper II, the expression could be measured in a 
panel of AML patients with rearrangements of chromosome region 12q1. 
The oncogenic potential of the involved genes can be investigated by functional 
studies as outlined in Table 4. Research in our laboratory is currently focused on 
describing the consequences of altered chromosomes rather than doing functional 
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analysis, so by publishing our results we hope that other researchers with more cell 
biological expertise will take the findings further. 
Today, fusion gene detection in the clinical diagnostic setting is based on FISH 
(mostly interphase FISH) or RT-PCR. Either as an array, or using targeted next 
generation sequencing, it will soon be feasible to detect all known gene fusions in 
cancer in a single experiment, also applicable in a diagnostic setting (Lovf et al, 2011, 
Lovf et al, 2013). As outlined in the discussion, all variants of disease specific 
rearrangements are important to investigate, as subtypes of them may impact 
prognosis. An updated database including all these chimeric transcripts is necessary 
for such an approach, and much effort has already been made to catalogue chimeric 
transcripts in databases (Frenkel-Morgenstern et al, 2013, Mitelman et al, 2013).  
In hematologic and lymphatic malignancies, monitoring of minimal residual disease 
can be performed by PCR analysis amplifying fusion genes (van der Velden et al, 
2003). This technique has been successfully used for detection of BCR-ABL fusion 
gene transcripts in CML (Bagg, 2002). Recent studies have demonstrated that this 
method is applicable also in solid tumors. By next generation sequencing, Leary and 
co-workers identified tumor-specific rearrangements in breast and colorectal cancer 
patients and were able to assess disease status and drug responsiveness by monitoring 
these disease-specific gene rearrangements (Leary et al, 2010). Although still too 
expensive in most diagnostic settings, this approach demonstrates another potential 
benefit of studying acquired mutations in cancer, independently of the oncogenic 
properties they may possess.  
A novel fusion gene such as IRF2BP2-CDX1 (paper III) would probably be a good 
individual biomarker for the patient in whom it was identified, regardless of the 
limited knowledge of its function. A nascent relapse would most probable be 
detectable by PCR targeting this fusion gene. If such fusion gene detection could be 
implemented in a clinical setting, it would probably save both recourses associated 
with conducting and interpreting the evaluations and the adverse effects linked to 
recurrent radiological evaluations. However, disease monitoring using “individual” 
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fusion genes requires that the mutations in question are in fact “primary” or “drivers” 
and that they are present in both the primary tumor and at relapse. A recent paper 
reported that among genes found to be mutated, only ~30% were found throughout the 
tumor parenchyma (Gerlinger et al, 2012). One approach to meet this issue is to 
investigate a panel of mutated genes, where one or more most probably will be present 
in all tumor cells.  
In order to obtain a better pathogenetic understanding of a specific tumor entity, a 
deeper investigation of one or a few well-characterized tumors using several methods 
(cytogenetics, RNA sequencing, gene expression profiling etc.) may reveal more about 
the pathogenesis than using one single approach applied to many, probably molecular 
distinct tumours (Liu, 2013). We hope our present and future studies of malignancies 
at different resolution levels will contribute to this development. 
A final note to the therapeutic potential of chimeric proteins caused by chromosomal 
rearrangements will round off this work. First, a protein product has to be important 
for tumor cell survival in order to make a good target for treatment. Second, it is easier 
to target a protein that results in a gain-of-function and has enzymatic activity, than a 
protein with numerous weak interactions (Vogelstein et al, 2013). Although 
development of treatments directed against fusion genes may seem like a challenging 
task, we must be patient in our search. Four decades passed from the identification of 
the Philadelphia chromosome to imatinib was approved for therapy against CML, but 
it was definitely worth the wait (Druker, 2008).  
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List of abbreviations 
ALL acute lymphoblastic leukemia 
AML acute myeloid leukemia 
BAC bacterial artificial chromosome 
cDNA complementary DNA 
CGH comparative genomic hybridization  
CML chronic myeloid leukemia 
DAPI 4',6-diamidino-2-phenylindole 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide 
ESTs expressed sequence tags 
FAB French American British 
FISH fluorescence in situ hybridization 
GISTs gastrointestinal stromal tumors 
HLA human leukocyte antigen 
IP-FISH interphase FISH  
ISCN International System for Human Cytogenetic Nomenclature 
LD-PCR long distance PCR 
MC mesenchymal chondrosarcoma 
M-FISH multiplex FISH  
miRNA micro RNA  
mRNA messenger RNA  
NCBI National Center for Biotechnology Information      
PCR polymerase chain reaction  
qPCR quantitative PCR (Real-time PCR) 
RACE-PCR rapid amplification of cDNA ends  
RNA ribonucleic acid 
RNA-seq RNA sequencing 
rRNA ribosomal RNA 
RT-PCR reverse transcription  
siRNA small interfering  
TKI tyrosine kinase inhibitor 
tRNA transfer RNA 
UCSC University of California, Santa Cruz 
WHO World Health Organization 
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Gene symbols 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 
ALK anaplastic lymphoma receptor tyrosine kinase 
BCR breakpoint cluster region 
CBFA2T3 core-binding factor, runt domain, alpha subunit 2; translocated to, 3 
CDX1 caudal type homeobox 1 
CDX2 caudal type homeobox 2 
DDIT3 DNA-damage-inducible transcript 3 
ETV6 ets variant 6 
EWSR1 EWS RNA-binding protein 1 
FLI1 Fli-1 proto-oncogene, ETS transcription factor 
FLT3 fms-related tyrosine kinase 3 
FUS fused in sarcoma 
GPC5 glypican 5 
GUSB glucuronidase, beta 
HEY1 hairy/enhancer-of-split related with YRPW motif 1 
HMGA2 high mobility group AT-hook 2 
HMGA2 high mobility group AT-hook 1  
IRF2 interferon regulatory factor 2 
IRF2BP2 
JAK2 
interferon regulatory factor 2 binding protein 2 
Janus kinase 2 
KANK1 KN motif and ankyrin repeat domains 1 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
L1TD1 LINE-1 type transposase domain containing 1 
MDM2 MDM2 oncogene, E3 ubiquitin protein ligase 
MYC v-myc avian myelocytomatosis viral oncogene homolog 
NCOA2 nuclear receptor coactivator 2 
NFIA nuclear factor I/A 
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 
PDGFRβ platelet-derived growth factor receptor, beta polypeptide 
PIGA phosphatidylinositol glycan anchor biosynthesis, class A 
RUNX1 runt-related transcription factor 1 
TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 68kDa 
TBP TATA box binding protein 
TNIK TRAF2 and NCK interacting kinase   
ZNF384 zinc finger protein 384 
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Abstract
Mesenchymal chondrosarcomas (MCs) account for 3–10% of primary chondrosarcomas. The cytogenetic literature includes
only ten such tumours with karyotypic information and no specific aberrations have been identified. Using a purely
molecular genetic approach a HEY1-NCOA2 fusion gene was recently detected in 10 of 15 investigated MCs. The fusion
probably arises through intrachromosomal rearrangement of chromosome arm 8 q. We report a new case of MC showing a
t(1;5)(q42;q32) as the sole karyotypic aberration. Through FISH and whole transcriptome sequencing analysis we found a
novel fusion between the IRF2BP2 gene and the transcription factor CDX1 gene arising from the translocation. The IRF2BP2-
CDX1 has not formerly been described in human neoplasia. In our hospital’s archives three more cases of MC were found,
and we examined them looking for the supposedly more common HEY1-NCOA2 fusion, finding it in all three tumours but
not in the case showing t(1;5) and IRF2BP2-CDX1 gene fusion. This demonstrates that genetic heterogeneity exists in
mesenchymal chondrosarcoma.
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Introduction
The classification of sarcomas describes over 50 different
histological subtypes [1]. In approximately 20% of them, recurrent
balanced translocations leading to formation of fusion genes were
identified [2]. Fusion genes provide diagnostic and sometimes
prognostic information on the tumours they characterize and
knowledge about them could ultimately lead to new targeted
therapies [3].
Mesenchymal chondrosarcomas (MCs) are rare tumours that
account for 3–10% of primary chondrosarcomas [1]. Their
typical histological appearance includes a biphasic pattern with
areas of round primitive mesenchymal cells interrupted by
chondroid elements [4]. Most cases are diagnosed in the second
and third decade of life and the prognosis is mostly poor, with a
5-year survival rate of about 50% [5]. Adequate surgery is the
gold standard for treatment of localized disease [6] and the role
of chemotherapy and radiotherapy remains poorly defined [7,8].
According to the Mitelman Database of Chromosome
Aberrations and Gene Fusions in Cancer [9], only ten MCs
have been karyotyped and no consistent cytogenetic findings
have been described. Recently, however, using a genome-wide
exon-resolution expression screen, a fusion between the hairy/
enhancer-of-split related with YRPW motif 1 (HEY1) gene and
the nuclear receptor coactivator 2 (NCOA2) gene was detected
in 10 out of 15 analysed MCs (67%) [10]. Both genes are
located on the long arm of chromosome 8 and so the fusion
presumably results from an intrachromosomal rearrangement,
probably a deletion (,9.6 Mb according to the UCSC browser,
assembly 2009).
We report the finding of a balanced t(1;5)(q42;q32) as the sole
karyotypic abnormality in an MC. The translocation led to a new
fusion between the interferon regulatory factor 2 binding protein 2
gene (IRF2BP2) and the caudal type homeobox 1 (CDX1) gene.
Based on the recent report by Wang et al (2012) [10], we also
examined archival material from another three MCs we had
access to for the presence of the HEY1-NCOA2 gene fusion, finding
it in all three.
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Materials and Methods
Patient Samples
Patient 1 was a 63-year-old female in whom a solitary tumour
mass was detected in the right cerebral hemisphere in August
2007. Examination of biopsy material revealed the tumour to be a
diffuse large B-cell lymphoma of activated B-cell subtype.
Cytogenetic analysis of this tumour was unsuccessful. Detailed
work-up for other manifestations of lymphoma was negative,
compatible with a diagnosis of primary central nervous system
lymphoma (PCNSL). However, a tumour in the left iliacus muscle
was detected, 3 cm in largest diameter. Biopsies revealed a spindle
cell tumour of uncertain malignant potential. The patient received
chemotherapy for PCNSL according to Abrey et al. [11] including
high-dose methotrexate and high-dose cytarabin. Evaluation after
7 courses of chemotherapy confirmed complete remission of her
PCNSL. There was no change in size of the tumour in the left iliac
muscle and in June 2008 a wide excision of it was performed. A
detailed work up of the tumour specimen revealed a small cell and
chondromatous tumour diagnosed as a mesenchymal chondro-
sarcoma (Figure 1A). Focal infiltrative growth and necroses were
present. Because of narrow margins, postoperative radiotherapy
2 Gy6 25 was given. A CNS recurrence of her lymphoma was
detected in November 2011, and the patient has received radiation
therapy. She remains without sign of recurrence of the MC at the
time of writing.
The Norwegian Radium Hospital (NRH) is the largest referral
centre for Norwegian patients with bone and soft tissue tumours
covering a population of 2.6 million. To identify additional
patients with a diagnosis of MC, a database search was performed
for cases with this disease. Three additional patients (patients 2–4)
were identified (see Table 1 for clinical details and Figure 1A for
histological image).
Ethics Statement
Written informed consent was obtained from patients 1 and 3.
In the latter case, one of the parents consented on the patient’s
behalf. Frozen tissue from deceased patients (patients 2 and 4) was
retrieved from The Radium Hospital biobank (project nr S-0747a
approved by the Regional Ethics Committee and The Directory of
Health (Helsedirektorat) in 2008). Specific permission to perform
RNA analysis/sequencing was obtained from patient 1 after
approval by the Regional Ethics Committee for Medical and
Health Research Ethics South-East (REC number: 2010/1389A).
The entire study was also approved by the institutional review
board at the Norwegian Radium Hospital. All data were analyzed
anonymously.
G-banding and karyotyping
Fresh tissue from a representative area of the tumour (patient 1)
was received and analysed as part of our diagnostic routine. The
samples were disaggregated mechanically and enzymatically with
collagenase II (Worthington, Freehold, NJ, USA). The resulting
cells were cultured and harvested using standard cytogenetic
techniques [12]. Chromosome preparations were G-banded with
Wright stain. The karyotype was written according to The
International System for Human Cytogenetic Nomenclature
(ISCN) 2009 guidelines [13]. Phytohemagglutinin (VWR, Oslo,
Norway) –stimulated leucocytes were obtained from peripheral
blood to determine the patient’s constitutional karyotype.
Fluorescence in Situ Hybridization Analysis
Fluorescence in situ hybridization (FISH) was performed using
probes from bacterial artificial chromosomes (BACs). BACs and
fosmid clones flanking and covering the breakpoint positions were
selected using the Human Genome Browser at the University of
California web site (Feb.2009/release: hg19, http://genome.ucsc.
edu/). The selected clones (see Table S1 for detailed information)
were purchased from Life Technologies (Carlsbad, CA, USA) or
the BACPAC Resource Center (Oakland, CA, USA).
Bacteria were cultured in selective media according to the
manufacturer’s recommendation. DNA was extracted using High
Pure Plasmid Isolation kit (Roche Applied Science, Penzberg,
Germany). DNA labelling was done in a nick translation reaction
and the synthesized probes were hybridized to previously G-
banded slides. All procedures were performed as previously
described [14]. The slides were counterstained with 49,6-
diamidino-2-phenylindole (DAPI). The analysis was done using a
CytoVision system (Applied Imaging, Newcastle, UK). All probes
were tested for their correct location on normal metaphase spreads
prior to use.
Material for Molecular Analysis
Representative samples of tumour tissue were frozen and stored
at 280uC after surgery. DNA was isolated using Genomic-tip
(Qiagen, Hilden, Germany) to obtain pure high molecular weight
DNA. RNA was extracted from tumour tissue using the Trizol
reagent (Life Technologies) with a homogenizer (Omni THQ
Digital Tissue Homogenizer, Kennesaw, GA, USA). The RNA
quality was evaluated using the Experion Automated Electropho-
resis System (Bio-Rad Laboratories, Hercules, CA, USA). cDNA
was synthesized using the iScript kit and random primers (Bio-Rad
Laboratories). All procedures were done according to the
manufacturers’ recommendations.
High-throughput Paired-end RNA-sequencing
Sequencing was performed according to the TruSeq paired-end
RNA-sequencing protocols from Illumina for Solexa sequencing
on a Genome Analyzer IIx with paired end module (Illumina Inc.,
San Diego, CA, USA). 3.5 mg total RNA was used as starting
material for library construction, using the TruSeq RNA Sample
Preparation Kit v2 where the steps include poly-A mRNA
isolation, fragmentation, and cDNA synthesis before adapters
are ligated to the products and amplified to a final cDNA library.
Shearing to about 150 bp fragments was achieved using divalent
cations under elevated temperature. Approximately 58 million
clusters were generated by the TruSeq PE Cluster Kit v2 on the
Illumina cBot Cluster Generation System, and 76 base pairs were
sequenced, from each side of the fragments, using reagents from
the TruSeq SBS Kit v5 (all kits from Illumina).
Gene Fusion Prediction
The Illumina software pipeline was used for processing of image
data into raw sequencing data (SCS 2.9 and Casava 1.8.2), and
only sequence reads marked as ‘‘passed filtering’’ were used in the
downstream data analysis. A total of 91 million reads were
obtained. We utilized the fusion discovery software deFuse (version
0.4.3) [15], with Ensembl release 65 reference genome (hg19) and
gene models, RepeatMasker, EST, and spliced EST annotations
downloaded from the University of California Santa Cruz Table
Browser (http://genome.ucsc.edu/, accessed May 2012). Uni-
Gene clusters were downloaded from National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov/, ac-
cessed May 2012) to assist in locating potential gene fusions. Three
spanning reads and two split reads were required to call sequence
reads a gene fusion.
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PCR and Sequencing
Primers used in PCR were designed with the FastPCR
software [16]. The full list of applied primers is given in Table 2.
The primers used for detection of the HEY1- NCOA2 fusion
were identical to the primers used by Wang et al [10]. cDNA
PCR was run using 2 ml cDNA in a 25 ml PCR reaction using
TaKaRa Ex Taq Hot Start (Takara Bio Inc, Shiga, Japan). The
PCR conditions were as follows: 98uC for 7 sec, 68uC for 2 min
after a 1 min initial denaturation at 98uC. 34 cycles were run.
Amplified products were cloned using the TOPO TA cloning
kit (Life Technologies). Selected products were sent for Sanger
sequencing (GATC Biotech, Konstanz, Germany) and obtained
sequences were analysed using BLAST (Basic Local Alignment
Search Tool, www.ncbi.nlm.nih.gov/BLAST/). All cases were
tested for expression of a zinc-finger gene suppressor of zeste 12
homolog (Drosophila) (SUZ12) to assess RNA quality.
Long Distance PCR
PCR experiments on genomic DNA were performed using
,100 ng DNA as template in 25 ml PCR reactions using TaKaRa
LA Taq following the manufacturer’s recommendations for LD-
PCR: 30 cycles of 98uC for 10 sec (denaturation) followed by 68uC
for 15 min (annealing and extension; Takara Bio Inc). PCR
products were purified using GeneJET PCR purification kit
(Fermentas GmbH, St. Leon-Rot, Germany) and sent for Sanger
sequencing (GATC Biotech).
Figure 1. Histological images of the four MCs and characteristics of the HEY1-NCOA2 fusion. (A) The typical biphasic histological pattern is
observed in all tumours. (B) The HEY1-NCOA2 fusion was detected using primers HEY1_F1 and NCOA2_E13-R3 in patients 2–4 but not in patient 1
whose tumour showed the t(1;5). (C) The HEY1-NCOA2 fusion was confirmed by sequencing. The breakpoint positions were identical to those
previously reported.
doi:10.1371/journal.pone.0049705.g001
Table 1. Patient characteristics.
Patient number Sex/age at diagnosis Histological diagnosis Location of primary tumour
Tumour material
analysed
1 F/63 Mesenchymal CS Left iliacus muscle
(soft tissue tumour)
Primary tumour
2 F/38 Mesenchymal CS Pelvic bone (bone tumour) Metastasis
3 F/12 Mesenchymal CS Vertebra (bone tumour) Primary tumour
4 F/39 Mesenchymal CS Vertebra and right thigh (bone and
soft tissue tumour)
Metastasis
F = female.
doi:10.1371/journal.pone.0049705.t001
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Results
The cytogenetic analysis of the only tumour (patient 1) from
which we got a fresh sample revealed a balanced t(1;5)(q42;q32) as
the sole abnormality in all cells analysed (Figure 2A). Analysis of
peripheral blood leukocytes displayed a normal female karyotype
ruling out the possibility of a constitutional aberration.
All cases (i.e., the tumour carrying a t(1;5) as well as the three
archival tumours) were tested for the HEY1-NCOA2 fusion which
was recently identified in 10 of 15 investigated MCs [10]. A PCR
product of approximately 300 bp was amplified from tumours 2,
3, and 4 but not from tumour 1. Subsequent sequencing analysis
confirmed the fusion between HEY1 exon 4 and NCOA2 exon 13
in cases 2–4, identical to the one previously described [10]
(Figures 1B and 1C). As no PCR product was amplified in tumour
1, i.e., the one showing the t(1;5), we assumed that a new fusion
gene was generated by the 1;5-rearrangement. To better
characterize the breakpoint on the rearranged chromosome 5, a
series of selected BAC clones mapping to the involved bands were
hybridized to metaphase plates. Clone CTC-802J2 mapping on
5q32 and covering four genes gave three signals on metaphase
chromosomes. The breakpoint position was further narrowed
down using fosmid clones with clone G248P81640F4 giving a split
signal, mapping the breakpoint to a genomic area between the
39end of the platelet derived growth factor receptor b gene
(PDGFRb) and the large intron 1 of CDX1.
Since the breakpoint region as delimited by FISH was large,
probably involving one of two genes, we decided to investigate the
translocation in detail using a whole transcriptome sequencing
approach focusing on potential fusion transcripts between
chromosomes 1 and 5. The deFuse algorithm [15], designed for
fusion gene discovery in paired-end RNA sequence data sets, gave
us a list of 92 putative fusions in the tumour transcriptome that we
reduced to 85 after removing isoforms of the same fusions (Table
S2). An IRF2BP2-CDX1 transcript involving two coding regions
yielded the highest split count value (number of split reads
supporting the fusion) of all the predicted fusions and was
predicted to be in-frame. We therefore chose to focus on this
putative fusion. cDNA PCR experiments with specific primers
were run to validate the IRF2BP2-CDX1 fusion. Two distinct
bands were identified using the primer IRF2BP2-895F, located in
exon 1, in combination with CDX1-771R, located in exon 3
(Table 2 and Figure 2C). The primer combination IRF2BP2-926F
and CDX1-659R yielded smaller but similar bands. Cloning of the
amplified PCR products was performed and sequencing was
carried out from six individual bacterial clones. IRF2BP2 exists as
two different isoforms where isoform B lacks 48 bp of exon 1
sequence representing 16 amino acids [17]. Sequencing analysis of
the PCR products confirmed the presence of both isoforms fused
to exon 2 of CDX1, i.e., an IRF2BP2-CDX1 fusion transcript was
confirmed in the tumour RNA. Both fusion transcripts were found
to be ‘‘in frame’’ and are predicted to encode proteins of 466 and
450 amino acids, respectively, before being terminated by a stop
codon. The reciprocal fusion between CDX1-IRF2BP2 did not
yield any products by cDNA PCR (primer combinations CDX1-
214F+IRF2BP2-1248R and CDX1-369F+IRF2BP2-1172R,
Table 2). The presence of the IRF2BP2-CDX1 fusion gene was
tested for in specimens from tumour 2–4 using primer combina-
tions IRF2BP2-926F and CDX1-771R (Table 2). None of the
specimens showed such fusion.
Next, we wanted to identify the genomic breakpoints of the
IRF2BP2-CDX1 fusion. Using primers IRF2BP2-926F and CDX1-
26970R (Table 2) we managed to amplify a product of about
800 bp which by sequencing was shown to contain the breakpoint,
i.e., sequencing analysis confirmed the predicted positions of the
genomic breakpoints. On chromosome 1 the breakpoint was in
intron 1 of IRF2BP2 (chr1:234743757 bp), whereas on chromo-
some 5 it was in the large intron 1 of CDX1 (chr5:149551799 bp).
To investigate the involvement of the IRF2BP2 gene also by
FISH, we hybridized BAC clones overlapping IRF2BP2 to
metaphases obtained from the cultured cells (Table S1). Signals
were detected on the normal chromosome 1 and the derivative
chromosome 1. However, no signal was seen on chromosome 5 as
would be expected if the IRF2BP2-CDX1 fusion had resulted from
a simple balanced translocation. These findings thus indicate that
a more complex rearrangement had taken place, possibly
including inversions at the breakpoint.
Discussion
The cytogenetic knowledge on mesenchymal chondrosarcomas
is limited to ten cases [9]. We report here a solitary t(1;5)(q42;q32)
in a case of MC. The translocation led to recombination of the
IRF2BP2 and CDX1 genes.
This is the first time an IRF2BP2-CDX1 fusion has been
detected in human neoplasia. CDX1 belongs to the homeobox
gene family [18]. These genes share a homebox domain that
encodes a DNA binding protein functioning as a transcription
Table 2. List of primers.
Primers Sequence (59 to 39) Tested fusion
HEY1_F1 CGAGGTGGAGAAGGAGAGTG HEY1-NCOA2
NCOA2_E13-R3 AGTTGGGCTTTGCAATGTGA HEY1-NCOA2
CDX1-214F CCGCAGTACCCCGACTTCTCCAG CDX1-IRF2BP2
CDX1-369F ATTCGGGCCCCCTCCAGACTTTA CDX1-IRF2BP2
CDX1-659R GTTCAGTGAGCCCCAGATTGGCAG IRF2BP2- CDX1
CDX1-771R TGATGTCGTGGGCCATCGGC IRF2BP2- CDX1
CDX1-26970R GTCTCAGGCTCCCCTTCGTGAGTGTGTC IRF2BP2- CDX1
IRF2BP2-895F CAAGAGCCGCGGGTCTGGAGA IRF2BP2- CDX1
IRF2BP2-926F GTCAACAGGCCCAAGACCGTGC IRF2BP2- CDX1
IRF2BP2-1172R CTTGAGCCCCTCTGTGGATGTGGA CDX1-IRF2BP2
IRF2BP2-1248R GTGTGGTCCGGTTGGAATGAGGTG CDX1-IRF2BP2
doi:10.1371/journal.pone.0049705.t002
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factor [19]. In particular, CDX1 is an upstream regulator of Hox-
gene expression [20] that has been implicated in malignancies
such as leukaemias [21,22]. In adults, CDX1 expression is
restricted to intestinal epithelium [23–25] and aberrant expression
has been linked to intestinal cancer [24,26–28]. No fusion gene
involving CDX1 has so far been described as opposed to another
member of the Cdx family, CDX2. CDX2 is overexpressed in both
lymphoid and myeloid leukaemias [29–31] and a fusion gene
resulting from a balanced t(12;13) leading to an ETV6-CDX2
fusion was detected in a patient with acute myeloid leukaemia
[32].
The first exon of IRF2BP2 forms the 5`end of the IRF2BP2-
CDX1 fusion. IRF2BP2 normally exists in two isoforms resulting
from alternative splicing of the gene [17]. Both variants contain a
Zinc finger motif at their N-terminus possibly binding DNA [17].
Although no direct link to cancer has been described for this gene,
IRF2BP2 interacts with partners that are involved in cancer as for
example the tumour suppressor gene TP53 [33] and the oncogene
IRF2 [17]. IRF2BP2 also acts as a co-repressor of IRF2, inhibiting
the expression of interferon-responsive genes. Recently also
NFAT1, which encodes a transcription factor involved in the cell
cycle, differentiation, and apoptosis, was shown to be repressed by
IRF2BP2 [34]. According to BioGPS [35], IRF2BP2 is expressed
in a variety of human tissues [36].
Two PCR products were obtained by cDNA PCR investigations
for the IRF2BP2-CDX1 fusion. The difference between the two
products was by sequencing shown to be caused by the alternative
splice variants of IRF2BP2. Both sequences were shown to be in
frame, with the largest transcript predicted to encode a 466 amino
acid protein and the smaller encoding 450 amino acids. The
Figure 2. Cytogenetic and molecular details of the IRF2BP2- CDX1 fusion gene. (A) Partial karyotype showing the aberrant chromosomes 1
and 5. Arrows point to the breakpoint positions. (B) Inverted DAPI metaphase harbouring the t(1;5). Upon hybridization with probe CTC-802J2
mapping to 5q32, three fluorescent signals were detected; (on the normal chromosome 5, the derivative chromosome 5, and the derivative
chromosome 1), indicating a breakpoint within the genomic area covered by this BAC. (C) In the upper panel, the structure of the wild type IRF2BP2
and CDX1 genes is shown in grey and black, respectively. Bars indicate positions of primers yielding products by cDNA PCR. For detailed primer
information, see Table 2. In the lower panel, the two identified fusion gene transcripts are illustrated. By sequencing the fusion was found to consist
of IRF2BP2 exon 1 (isoform A or B) fused to exon 2 of CDX1. The base sequence shown originates from isoform A. A gel blot demonstrating the two
PCR products is shown in the right panel. The primer combinations used are specified. (D) Illustration of hypothetical fusion protein. The N` terminal
part of the protein originates from IRF2BP2 and harbour a zinc finger motif which may bind DNA [17]. The C` terminal part contains a homeodomain
which may also interact with the DNA double helix (http://www.ncbi.nlm.nih.gov/gene/1044, accessed August 2012).
doi:10.1371/journal.pone.0049705.g002
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biological implications of the predicted fusion protein IRF2BP2-
CDX1 can only be speculated upon, but as both fusion partners
are involved in transcriptional regulation, a protein disturbing
DNA transcription is likely. The IRF2BP2-CDX1 fusion is thus
suggested to take part in MC tumorigenesis and/or progression.
MCs are rare, and at our institution only five patients (four
included in this study) received this diagnosis during the last 25
years. We identified the HEY1-NCOA2 in three of these tumours
(patients 2, 3, and 4), confirming that this fusion gene is common
in MC. In a majority of the well-known translocation-related
sarcomas such as myxoid liposarcoma and low-grade fibromyxoid
sarcoma, more than one defining fusion variant has been detected.
Often one fusion variant is more common than the others [2,3].
IRF2BP2-CDX1 could be such an additional fusion variant
identified in a subset of MCs, but only analysis of larger series of
tumours can determine the prevalence of the IRF2BP2-CDX1.
Of possible interest is the fact that the three HEY1-NCOA2-
positive MCs all had tumour manifestations detected in bone,
whereas the MC showing the t(1;5) and IRF2BP2-CDX1 fusion
originated from soft tissue. Although most common in bone, one-
fifth to one-third of MCs do arise in soft tissue [4]. The tissue of
manifestation was not reported in the MCs where the HEY1-
NCOA2 was first described [10]. Given the rarity of these tumours,
only future surveys of larger groups of patients can clarify if there is
a correlation between the tissue the tumour affects and the type of
fusion gene present. This study demonstrates the feasibility and
indeed advantage of using karyotyping and molecular cytogenetic
methods together with transcriptome sequencing to identify fusion
genes caused by chromosomal rearrangements. Traditionally,
chromosome walking using BACs or equivalent probes has been
used to narrow down the breakpoint regions followed by PCR
based analyses to amplify the genes involved in the breakpoints.
Submicroscopic rearrangements in the breakpoint area can cause
considerable confusion, however, and prevent amplification of
fusion genes. Using whole-transcriptome sequencing without prior
genetic knowledge of the tumour investigated can also be
challenging as validation of numerous predicted fusion gene
transcripts is necessary. To know which chromosomes take part in
the rearrangement therefore helps considerably when looking for
novel putative cancer-specific fusion genes.
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High-throughput sequencing identiﬁes an NFIA/CBFA2T3 fusion
gene in acute erythroid leukemia with t(1;16)(p31;q24)
Leukemia (2013) 27, 980–982; doi:10.1038/leu.2012.266
In a previous publication of ours1 we showed the involvement of
the myeloid translocation gene-related protein 2 gene (CBFA2T3)
in a case of acute erythroid leukemia with the translocation
t(1;16)(p31;q24). Because of lack of material available for analysis,
we could not with certainty determine the leukemogenic
mechanism, whether it be generation of a fusion gene with
CBFA2T3 as one of the partners or loss of tumor suppressor
activity, in which case genes KANK1and L1TD1, both
homozygously lost, might be of the essence.
Some months after our article was published we got hold of
2ml coagulated blood with 3% of abnormal cells from the same
patient. As sequencing technology has also developed very fast
lately, we decided to extract RNA from the sample and try to use it
for high-throughput sequence analysis. The RNA was extracted
and its quality checked by the Experion automated electrophor-
esis system (Bio-Rad Laboratories, Hercules, CA, USA). A total of
3 mg of RNA was sent for high-throughput pair-end RNA-
sequencing to the Norwegian Sequencing Center at the Ullevål
Hospital (http://www.sequencing.uio.no/). The Illumina software
pipeline was used to process image data into raw sequencing data
and only sequence reads marked as ‘passed ﬁltering’ were used in
the downstream data analysis. A total of 107 million reads were
obtained. The FASTQC software was used for quality control of the
raw sequence data (http://www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc/). We used the fusion discovery software FusionMap
(release date 16-04-2012)2 and the pre-built Human B37 and
RefGene from the FusionMap website (http://www.omicsoft.com/
fusionmap/). A list of over 500 possible fusion genes was obtained.
A speciﬁc fusion involving the CBFA2T3 gene, which maps to
chromosome band 16q24, and the nuclear factor I/A (NFIA) gene,
which maps to chromosome band 1p31, was identiﬁed as number
10 in the list (seed count-rank 48; Supplementary Table 1). The
involvement of the NFIA gene ﬁts well with the ﬂuorescence in situ
hybridization (FISH) data on chromosome 1 previously obtained
and published.1 The presence of the NFIA/CBFA2T3 fusion was
veriﬁed by PCR using the NFIA-956 F and CBFA2T3–622 R primer
combination (Supplementary Table 2). A speciﬁc PCR product of
about 500 bp was identiﬁed and directly sequenced (Figure 1a).
The speciﬁc fusion occurs between exon 6 of the NFIA gene
(accession number NM_001134673.3) and exon 3 of the CBFA2T3
gene (accession number NM_005187.5; Figure 1b).
The NFIA/CBFA2T3 fusion gave an open reading frame and is
expected to lead to a chimeric protein containing 208 amino-acid
residues from NFIA (according to NP_001128145.1) and 603
residues from CBFA2T3 (according to NP_005178.4). The predicted
fusion protein should thus consist of 811 amino acids (Figure 1c).
The NFIA gene encodes a member of the NFI family of
transcription factors (http://genome.ucsc.edu). Interestingly, it
has been found that NFIA exhibits a marked lineage-speciﬁc
expression pattern in normal human hematopoiesis; it is
upregulated in the erythroid lineage but fully suppressed in
granulocytopoiesis.3 It has been shown that in early
hematopoiesis, the NFIA expression level acts as a factor
channeling hematopoietic progenitor cells into either the
erythroid or granulocytopoietic lineage.3 The NFI proteins have a
DNA-binding and dimerization domain in their N-terminal half,
which contains four cysteine residues, and a transactivation and
repression domain in their C-terminal half.4 The NFIA gene was
found involved in an NFIA/EHF chimeric fusion in one breast
cancer cell line out of 24 breast tumors analyzed (nine cell lines
and 15 primary tumors).5 However, its role as either a passenger
event or a direct, albeit infrequent, contributor to breast cancer
development remains uncertain.
CBFA2T3 encodes an ETO myeloid translocation gene family
protein, which interacts with DNA-bound transcription factors and
recruits a variety of corepressors to facilitate transcriptional
repression.6–8 The t(16;21)(q24;q22) translocation is one of the
less common karyotypic abnormalities speciﬁcally associated with
acute myeloid leukemia (AML). The translocation produces a
chimeric gene made up of the 5’-region of the runt-related
transcription factor 1 (RUNX1) gene fused to the 30-region of
CBFA2T3 (Figure 1d). In AMLs with either t(8;21) or t(16;21), the
transcription factor RUNX1 is juxtaposed to one of the zinc ﬁnger
nuclear proteins CBFA2T1 and CBFA2T3, respectively, resulting in
transcriptional repression of RUNX1 target genes.6 Lately, its
involvement as a partner in fusion genes was underlined by the
identiﬁcation of a IGH/CBFA2T3 fusion in a case of Burkitt
lymphoma and a diffuse large B-cell lymphoma.9 This gene is
also a putative breast tumor suppressor.10,11 Interestingly, CBFA2T3
is downregulated during erythroid differentiation, and it has been
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suggested to have a repressive role in early, as well as late human
erythroid differentiation.12 Hildebrand et al.6 demonstrated that
the nuclear protein ETO (eight-twenty-one, a family to which also
CBFA2T1, CBFA2T2 and CBFA2T3 belong) does not show reduced
repressor activity even if it lacks the ﬁrst 236 amino acids. As in the
present fusion the altered CBFA2T3 protein lacks only the ﬁrst 50
amino acids, we assume that its repressor activity is still retained
(Figure 1e). More speciﬁcally, we hypothesize a pathogenetic
parallel between AML showing a t(8;21) or t(16;21) and the present
erythroleukemia with the 1;16-translocation with transcriptional
repression of the NFIA target genes in the present case.
As the karyotype was described as 46,XY,der(1)t(1;1)(p31;q21),-
del(1)(p11p31),der(16)t(1;16)(p31;q24), that is, presented additional
rearrangement besides the 1;16-translocation, we decided to screen
the list of possible fusion genes in search of genes located in
karyotypic breakpoints to see if those were involved in fusions as
well. We identiﬁed four possible fusions (seed count-rank 412)
where one of the genes mapped to a breakpoint position on
chromosome 1. An analysis of the hypothetical fusions using the
BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi) showed in
one of the two genes high-sequence identity with several genes
and/or numerous repetitive sequences (for example, SINE). Hence,
the reality of the putative fusions was seriously called into question
and no further investigations were undertaken.
In addition to the present case, two more cases of
erythroleukemia showing a t(1;16)(p31;q24) in their karyotype13,14
can be found in the Mitelman Database of Chromosome
Aberrations and Gene Fusions in Cancer.15 All three patients
(including ours) were very young children, and clinical outcome
was poor. We assume that a NFIA/CBFA2T3 fusion existed also in
these leukemias, but no evidence is at hand to corroborate or
falsify this assumption.
In summary, we describe the ﬁrst fusion gene identiﬁed in acute
erythroleukemia. Knowledge of its speciﬁc functions in the
neoplastic context is still incomplete, but pathogenetic similarities
with other leukemic fusion genes are readily discernible. As for
other leukemias characterized genetically by fusion genes, one
may assume that the detailed pathogenetic knowledge now
emerging may eventually form a starting point from which
therapeutic attempts may begin.
Figure 1. Detection of the NFIA/CBFA2T3 fusion. (a) Gel picture showing the ampliﬁed fragment. Lane 1: ladder, lane 2: PCR product obtained
with primer combination NFIA-924 F and CBFA2T3–622 R, lane 3: product of the NESTED-PCR obtained with primer combination NFIA-956 F
and CBFA2T3–598 R. (b) Partial chromatogram showing the junction of the NFIA and CBFA2T3 genes. (c) Deduced amino acid sequence of the
fusion transcript. (d) Schematic overview of the breakpoint region of the NFIA and CBFA2T3 genes. The exons are not in scale. Arrows point to
primer positions. (e) Schematic overview of the position of the different domains of the NFIA and CBFA2T3 proteins and the NFIA/CBFA2T3
chimeric protein, according to ensembl (http://www.ensembl.org/index.html).
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